Identification

Name
Tetracycline
Accession Number
DB00759  (APRD00572)
Type
Small Molecule
Groups
Approved, Vet approved
Description

Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.

Structure
Thumb
Synonyms
  • (4S,4aS,5aS,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
  • Abramycin
  • Anhydrotetracycline
  • Deschlorobiomycin
  • Tetracyclin
  • Tétracycline
  • Tetracyclinum
  • Tetrazyklin
  • Tsiklomitsin
Product Ingredients
IngredientUNIICASInChI Key
Tetracycline hydrochlorideP6R62377KV64-75-5YCIHPQHVWDULOY-FMZCEJRJSA-N
Tetracycline phosphateNZ662XY5PP13930-32-0WXDJNRXQVCECPF-IZGCTLQUSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Achromycin Ont Oph 1%Ointment1 %OphthalmicLederle Cyanamid Canada Inc.1955-12-311997-08-14Canada
Achromycin VCapsule250 mg/1OralHeritage2013-10-18Not applicableUs
Achromycin VCapsule500 mg/1OralHeritage2013-10-18Not applicableUs
Achromycin V Cap 250mgCapsule250 mgOralLederle Cyanamid Canada Inc.1957-12-311997-08-14Canada
ActisiteFiber, extended release12.7 mgDentalProcter And GambleNot applicableNot applicableCanada
Apo Tetra Tabs 250mgTablet250 mgOralApotex Corporation1984-12-312008-08-21Canada
Jaa Tetra Tab 250mgTablet250 mgOralJaapharm Canada Inc.1993-12-312016-08-10Canada
Medicycline Cap 250mgCapsule250 mgOralMedic Laboratory LtÉe1962-12-311996-09-09Canada
TetracyclineCapsule250 mgOralAa Pharma Inc1983-12-31Not applicableCanada
Tetracycline 1% Onguent OphthalmicOintment10 mgOphthalmicLaboratoires Sterigen Inc1988-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Novo-tetra 250mgTablet250 mgOralNovopharm Limited1967-12-312008-08-20Canada
Novo-tetra 250mgCapsule250 mgOralNovopharm Limited1967-12-312008-08-20Canada
Novo-tetra Sus 125mg/5mlLiquid125 mgOralNovopharm Limited1967-12-312005-08-10Canada
Nu-tetra Capsules 250mgCapsule250 mgOralNu Pharm Inc1990-12-312012-09-04Canada
SumycinTablet, film coated500 mg/1OralPar Pharmaceutical2017-04-04Not applicableUs
SumycinTablet, film coated250 mg/1OralPar Pharmaceutical2017-04-04Not applicableUs
Tetracycline HydrochlorideCapsule250 mg/1OralLiberty Pharmaceuticals, Inc.2000-01-31Not applicableUs00172 2416 80 nlmimage10 a00ed066
Tetracycline HydrochlorideCapsule250 mg/1OralRemedy Repack2011-05-162017-04-20Us
Tetracycline HydrochlorideCapsule250 mg/1OralHarris Pharmaceutical, Inc.1988-08-12Not applicableUs
Tetracycline HydrochlorideCapsule500 mg/1OralStat Rx USA2010-03-232018-02-08Us
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AcnecyclineOintment.03 mg/mLTopicalPhillips Company2011-02-15Not applicableUs
DermaclineOintment30 mg/mLTopicalInventus, Llc2016-11-08Not applicableUs
DiabeclineOintment30 mg/mLTopicalThru Pharma, Llc2013-05-23Not applicableUs
DiabeclineOintment30 mg/gTopicalPhillips Company2013-06-10Not applicableUs
DyabetexOintment.03 mg/mLTopicalPhillips Company2010-08-24Not applicableUs
Tetra-abcOintment.03 mg/mLTopicalPhillips Company2010-08-24Not applicableUs
Tetracycline 3 percent a First Aid AntibioticOintment30 mg/gTopicalPatient Focused Tele Health, Llc2018-02-02Not applicableUs
Tetracycline-ABCOintment.03 mg/mLTopicalPhillips Company2011-02-15Not applicableUs
TetraNextOintment30 mg/mLTopicalSaxet Pharmaceuticals2016-08-01Not applicableUs
TetraStemOintment30 mg/gTopicalPhillips Company2014-02-25Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
PyleraTetracycline hydrochloride (125 mg/1) + Bismuth subcitrate potassium (140 mg/1) + Metronidazole (125 mg/1)CapsuleOralPhysicians Total Care, Inc.2010-08-18Not applicableUs
PyleraTetracycline hydrochloride (125 mg/1) + Bismuth subcitrate potassium (140 mg/1) + Metronidazole (125 mg/1)CapsuleOralAllergan2013-08-01Not applicableUs
PyleraTetracycline hydrochloride (125 mg) + Bismuth subcitrate potassium monohydrate (40 mg) + Metronidazole (125 mg)CapsuleOralAptalis Pharma Inc.Not applicableNot applicableCanada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
FIRST Marys Mouthwash CompoundingTetracycline hydrochloride + Diphenhydramine hydrochloride + Hydrocortisone + NystatinKitOralCutis Pharma, Inc.2010-12-152017-10-04Us
International/Other Brands
Achromycin / Liquamycin
Categories
UNII
F8VB5M810T
CAS number
60-54-8
Weight
Average: 444.4346
Monoisotopic: 444.153265754
Chemical Formula
C22H24N2O8
InChI Key
OFVLGDICTFRJMM-WESIUVDSSA-N
InChI
InChI=1S/C22H24N2O8/c1-21(31)8-5-4-6-11(25)12(8)16(26)13-9(21)7-10-15(24(2)3)17(27)14(20(23)30)19(29)22(10,32)18(13)28/h4-6,9-10,15,25,27-28,31-32H,7H2,1-3H3,(H2,23,30)/t9-,10-,15-,21+,22-/m0/s1
IUPAC Name
(4S,4aS,5aS,6S,12aS)-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
SMILES
[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O

Pharmacology

Indication

Used to treat bacterial infections such as Rocky Mountain spotted fever, typhus fever, tick fevers, Q fever, rickettsialpox and Brill-Zinsser disease. May be used to treat infections caused by Chlamydiae spp., B. burgdorferi (Lyme disease), and upper respiratory infections caused by typical (S. pneumoniae, H. influenzae, and M. catarrhalis) and atypical organisms (C. pneumoniae, M. pneumoniae, L. pneumophila). May also be used to treat acne. Tetracycline may be an alternative drug for people who are allergic to penicillin.

Associated Conditions
Pharmacodynamics

Tetracycline is a short-acting antibiotic that inhibits bacterial growth by inhibiting translation. It binds to the 30S ribosomal subunit and prevents the amino-acyl tRNA from binding to the A site of the ribosome. It also binds to some extent to the 50S ribosomal subunit. This binding is reversible in nature. Additionally tetracycline may alter the cytoplasmic membrane of bacteria causing leakage of intracellular contents, such as nucleotides, from the cell.

Mechanism of action

Tetracycline passively diffuses through porin channels in the bacterial membrane and reversibly binds to the 30S ribosomal subunit, preventing binding of tRNA to the mRNA-ribosome complex, and thus interfering with protein synthesis.

TargetActionsOrganism
A30S ribosomal protein S7
inhibitor
Escherichia coli (strain K12)
A30S ribosomal protein S14
inhibitor
Escherichia coli (strain K12)
A30S ribosomal protein S3
inhibitor
Escherichia coli (strain K12)
A30S ribosomal protein S8
inhibitor
Escherichia coli (strain K12)
A30S ribosomal protein S19
inhibitor
Escherichia coli (strain K12)
A16S rRNA
inhibitor
Enteric bacteria and other eubacteria
UMajor prion protein
inhibitor
Human
UMultidrug translocase MdfANot AvailableEscherichia coli
UProtein-arginine deiminase type-4Not AvailableHuman
Absorption

Bioavailability is less than 40% when administered via intramuscular injection, 100% intravenously, and 60-80% orally (fasting adults). Food and/or milk reduce GI absorption of oral preparations of tetracycline by 50% or more.

Volume of distribution
Not Available
Protein binding

20 - 67% protein bound

Metabolism

Not metabolized

Route of elimination

They are concentrated by the liver in the bile and excreted in the urine and feces at high concentrations in a biologically active form.

Half life

6-12 hours

Clearance
Not Available
Toxicity

LD50=808mg/kg (orally in mice)

Affected organisms
  • Enteric bacteria and other eubacteria
  • Borrelia burgdorferi
  • Chlamydia trachomatis
  • Mycoplasma pneumoniae
  • Rickettsia rickettsii
  • Vibrio cholerae
  • Escherichia coli
  • Shigella
  • Coxiella
Pathways
PathwayCategory
Tetracycline Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(R)-warfarinTetracycline may increase the anticoagulant activities of (R)-warfarin.Experimental
(S)-WarfarinTetracycline may increase the anticoagulant activities of (S)-Warfarin.Experimental, Investigational
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when Tetracycline is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when 3,4-Methylenedioxyamphetamine is combined with Tetracycline.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Tetracycline.Experimental, Illicit
4-hydroxycoumarinTetracycline may increase the anticoagulant activities of 4-hydroxycoumarin.Experimental
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Methoxyamphetamine is combined with Tetracycline.Experimental, Illicit
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Tetracycline is combined with 5-methoxy-N,N-dimethyltryptamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Tetracycline.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Tetracycline.Experimental
AbemaciclibThe serum concentration of Tetracycline can be increased when it is combined with Abemaciclib.Approved, Investigational
AcenocoumarolTetracycline may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Tetracycline.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Tetracycline.Approved
AcetaminophenThe serum concentration of Tetracycline can be increased when it is combined with Acetaminophen.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Tetracycline.Approved, Vet Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Acetophenazine is combined with Tetracycline.Approved
Acetylcysteine zincAcetylcysteine zinc can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Acetylglycinamide chloral hydrateThe risk or severity of adverse effects can be increased when Acetylglycinamide chloral hydrate is combined with Tetracycline.Experimental
AcitretinThe risk or severity of adverse effects can be increased when Tetracycline is combined with Acitretin.Approved
AcyclovirThe excretion of Acyclovir can be decreased when combined with Tetracycline.Approved
AdapaleneThe risk or severity of adverse effects can be increased when Tetracycline is combined with Adapalene.Approved
AdinazolamThe risk or severity of adverse effects can be increased when Adinazolam is combined with Tetracycline.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Tetracycline.Investigational
AfatinibThe serum concentration of Tetracycline can be increased when it is combined with Afatinib.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Tetracycline.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Tetracycline is combined with Alaproclate.Experimental
AlbendazoleThe serum concentration of Tetracycline can be increased when it is combined with Albendazole.Approved, Vet Approved
AlcuroniumThe therapeutic efficacy of Alcuronium can be increased when used in combination with Tetracycline.Experimental
AlectinibThe serum concentration of Tetracycline can be increased when it is combined with Alectinib.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Tetracycline.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Tetracycline.Approved, Illicit
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Tetracycline.Approved, Vet Approved
AlitretinoinThe risk or severity of adverse effects can be increased when Tetracycline is combined with Alitretinoin.Approved, Investigational
AllobarbitalThe risk or severity of adverse effects can be increased when Allobarbital is combined with Tetracycline.Experimental
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Tetracycline.Investigational
AllopurinolThe excretion of Allopurinol can be decreased when combined with Tetracycline.Approved
AlmasilateAlmasilate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlmotriptanThe risk or severity of adverse effects can be increased when Tetracycline is combined with Almotriptan.Approved, Investigational
AloglutamolAloglutamol can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AlosetronThe risk or severity of adverse effects can be increased when Tetracycline is combined with Alosetron.Approved, Withdrawn
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Tetracycline.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Tetracycline.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tetracycline.Approved, Illicit, Investigational
AlprenololThe risk or severity of adverse effects can be increased when Tetracycline is combined with Alprenolol.Approved, Withdrawn
AlprostadilThe excretion of Alprostadil can be decreased when combined with Tetracycline.Approved, Investigational
AluminiumAluminium can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium phosphateAluminium phosphate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AlverineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Alverine.Approved, Investigational
AmdinocillinThe therapeutic efficacy of Amdinocillin can be decreased when used in combination with Tetracycline.Investigational, Withdrawn
AmikacinThe risk or severity of adverse effects can be increased when Amikacin is combined with Tetracycline.Approved, Investigational, Vet Approved
AmineptineThe risk or severity of adverse effects can be increased when Amineptine is combined with Tetracycline.Illicit, Withdrawn
Aminohippuric acidThe excretion of Tetracycline can be decreased when combined with Aminohippuric acid.Approved, Investigational
AmiodaroneThe serum concentration of Tetracycline can be increased when it is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Tetracycline.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Tetracycline.Approved
AmitriptylinoxideThe risk or severity of adverse effects can be increased when Amitriptylinoxide is combined with Tetracycline.Approved, Investigational
AmlodipineThe serum concentration of Tetracycline can be increased when it is combined with Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Tetracycline.Approved, Illicit
AmodiaquineThe serum concentration of Tetracycline can be increased when it is combined with Amodiaquine.Approved, Investigational
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Tetracycline.Approved
AmoxicillinThe therapeutic efficacy of Amoxicillin can be decreased when used in combination with Tetracycline.Approved, Vet Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Tetracycline.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Tetracycline.Approved, Illicit, Investigational
AmpicillinThe therapeutic efficacy of Ampicillin can be decreased when used in combination with Tetracycline.Approved, Vet Approved
AmprenavirThe metabolism of Tetracycline can be decreased when combined with Amprenavir.Approved, Investigational
AmsacrineThe serum concentration of Tetracycline can be increased when it is combined with Amsacrine.Approved, Investigational
AniracetamThe risk or severity of adverse effects can be increased when Aniracetam is combined with Tetracycline.Experimental
AnnamycinThe serum concentration of Tetracycline can be increased when it is combined with Annamycin.Investigational
ApalutamideThe serum concentration of Tetracycline can be decreased when it is combined with Apalutamide.Approved, Investigational
APD791The risk or severity of adverse effects can be increased when Tetracycline is combined with APD791.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Apomorphine.Approved, Investigational
ApramycinThe risk or severity of adverse effects can be increased when Tetracycline is combined with Apramycin.Experimental, Vet Approved
AprepitantThe serum concentration of Tetracycline can be increased when it is combined with Aprepitant.Approved, Investigational
AprobarbitalThe risk or severity of adverse effects can be increased when Aprobarbital is combined with Tetracycline.Approved, Illicit
ApronalideThe risk or severity of adverse effects can be increased when Apronalide is combined with Tetracycline.Experimental
Arbaclofen PlacarbilThe risk or severity of adverse effects can be increased when Arbaclofen Placarbil is combined with Tetracycline.Investigational
ArbekacinThe risk or severity of adverse effects can be increased when Tetracycline is combined with Arbekacin.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tetracycline.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of adverse effects can be increased when Aripiprazole lauroxil is combined with Tetracycline.Approved, Investigational
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Tetracycline.Approved
AspartameThe excretion of Tetracycline can be decreased when combined with Aspartame.Approved, Nutraceutical
AspoxicillinThe therapeutic efficacy of Aspoxicillin can be decreased when used in combination with Tetracycline.Experimental
AstemizoleThe serum concentration of Tetracycline can be increased when it is combined with Astemizole.Approved, Withdrawn
AtalurenThe excretion of Tetracycline can be decreased when combined with Ataluren.Approved, Investigational
AtazanavirThe metabolism of Tetracycline can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe risk or severity of adverse effects can be increased when Atomoxetine is combined with Tetracycline.Approved
AtorvastatinThe serum concentration of Tetracycline can be increased when it is combined with Atorvastatin.Approved
AtovaquoneThe serum concentration of Atovaquone can be decreased when it is combined with Tetracycline.Approved
AtracuriumThe therapeutic efficacy of Atracurium can be increased when used in combination with Tetracycline.Approved, Experimental, Investigational
Atracurium besylateThe therapeutic efficacy of Atracurium besylate can be increased when used in combination with Tetracycline.Approved
AvatrombopagThe excretion of Tetracycline can be decreased when combined with Avatrombopag.Approved, Investigational
AvibactamThe excretion of Avibactam can be decreased when combined with Tetracycline.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Tetracycline.Investigational, Vet Approved
AZD-3043The risk or severity of adverse effects can be increased when AZD-3043 is combined with Tetracycline.Investigational
AzelastineTetracycline may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzidocillinThe therapeutic efficacy of Azidocillin can be decreased when used in combination with Tetracycline.Approved
AzithromycinThe serum concentration of Tetracycline can be increased when it is combined with Azithromycin.Approved
AzlocillinThe therapeutic efficacy of Azlocillin can be decreased when used in combination with Tetracycline.Approved
BacampicillinThe therapeutic efficacy of Bacampicillin can be decreased when used in combination with Tetracycline.Approved, Investigational
Bacillus calmette-guerin substrain connaught live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Tetracycline.Approved, Investigational
Bacillus calmette-guerin substrain danish 1331 live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Tetracycline.Investigational
Bacillus calmette-guerin substrain tice live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Tetracycline.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Tetracycline.Approved
Bafilomycin A1The serum concentration of Tetracycline can be increased when it is combined with Bafilomycin A1.Experimental
Bafilomycin B1The serum concentration of Tetracycline can be increased when it is combined with Bafilomycin B1.Experimental
BarbexacloneThe risk or severity of adverse effects can be increased when Barbexaclone is combined with Tetracycline.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Tetracycline.Illicit
BaricitinibThe excretion of Baricitinib can be decreased when combined with Tetracycline.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Tetracycline.Investigational
BeclamideThe risk or severity of adverse effects can be increased when Beclamide is combined with Tetracycline.Experimental
BekanamycinThe risk or severity of adverse effects can be increased when Tetracycline is combined with Bekanamycin.Experimental
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Tetracycline.Withdrawn
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Tetracycline.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Tetracycline.Approved, Investigational
BenzoctamineThe risk or severity of adverse effects can be increased when Benzoctamine is combined with Tetracycline.Approved
Benzoic AcidThe excretion of Tetracycline can be decreased when combined with Benzoic Acid.Approved, Investigational
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Tetracycline.Approved, Illicit
BenzquinamideThe serum concentration of Tetracycline can be increased when it is combined with Benzquinamide.Withdrawn
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Tetracycline.Approved
BenzylpenicillinThe therapeutic efficacy of Benzylpenicillin can be decreased when used in combination with Tetracycline.Approved, Vet Approved
Benzylpenicilloyl PolylysineThe therapeutic efficacy of Benzylpenicilloyl Polylysine can be decreased when used in combination with Tetracycline.Approved
BepridilThe serum concentration of Tetracycline can be increased when it is combined with Bepridil.Approved, Withdrawn
BexaroteneThe risk or severity of adverse effects can be increased when Tetracycline is combined with Bexarotene.Approved, Investigational
BicalutamideThe serum concentration of Tetracycline can be increased when it is combined with Bicalutamide.Approved
BifemelaneThe risk or severity of adverse effects can be increased when Bifemelane is combined with Tetracycline.Experimental
BifeprunoxThe risk or severity of adverse effects can be increased when Bifeprunox is combined with Tetracycline.Investigational
Biricodar dicitrateThe serum concentration of Tetracycline can be increased when it is combined with Biricodar dicitrate.Investigational
Bismuth subcitrate potassiumThe serum concentration of Tetracycline can be decreased when it is combined with Bismuth subcitrate potassium.Approved, Investigational
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Bismuth SubsalicylateThe serum concentration of Tetracycline can be decreased when it is combined with Bismuth Subsalicylate.Approved, Vet Approved
BL-1020The risk or severity of adverse effects can be increased when BL-1020 is combined with Tetracycline.Investigational
BlonanserinThe risk or severity of adverse effects can be increased when Blonanserin is combined with Tetracycline.Approved, Investigational
BoceprevirThe metabolism of Tetracycline can be decreased when combined with Boceprevir.Approved, Withdrawn
BosentanThe serum concentration of Tetracycline can be decreased when it is combined with Bosentan.Approved, Investigational
Botulinum Toxin Type AThe risk or severity of adverse effects can be increased when Tetracycline is combined with Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BThe risk or severity of adverse effects can be increased when Tetracycline is combined with Botulinum Toxin Type B.Approved, Investigational
Brefeldin AThe serum concentration of Tetracycline can be increased when it is combined with Brefeldin A.Experimental
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Tetracycline.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tetracycline.Approved
BrivaracetamThe risk or severity of adverse effects can be increased when Brivaracetam is combined with Tetracycline.Approved, Investigational
BrofaromineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Tetracycline.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tetracycline.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Tetracycline.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Tetracycline.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Tetracycline.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Tetracycline.Approved, Investigational, Withdrawn
BufotenineThe risk or severity of adverse effects can be increased when Bufotenine is combined with Tetracycline.Experimental, Illicit
BumetanideThe excretion of Tetracycline can be decreased when combined with Bumetanide.Approved
BuprenorphineTetracycline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Tetracycline.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Tetracycline.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Tetracycline.Approved, Illicit
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Tetracycline.Approved, Illicit
ButaperazineThe risk or severity of adverse effects can be increased when Butaperazine is combined with Tetracycline.Experimental
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Tetracycline.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tetracycline.Approved, Illicit, Vet Approved
ButriptylineThe risk or severity of adverse effects can be increased when Butriptyline is combined with Tetracycline.Approved
CabazitaxelThe serum concentration of Tetracycline can be increased when it is combined with Cabazitaxel.Approved
CabergolineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Cabergoline.Approved
CaffeineThe serum concentration of Tetracycline can be increased when it is combined with Caffeine.Approved
Calcium AcetateThe serum concentration of Tetracycline can be decreased when it is combined with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe serum concentration of Tetracycline can be decreased when it is combined with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe serum concentration of Tetracycline can be decreased when it is combined with Calcium Chloride.Approved
Calcium CitrateThe serum concentration of Tetracycline can be decreased when it is combined with Calcium Citrate.Approved
Calcium glubionateThe serum concentration of Tetracycline can be decreased when it is combined with Calcium glubionate.Approved
Calcium GluceptateThe serum concentration of Tetracycline can be decreased when it is combined with Calcium Gluceptate.Approved
Calcium gluconateThe serum concentration of Tetracycline can be decreased when it is combined with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe serum concentration of Tetracycline can be decreased when it is combined with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe serum concentration of Tetracycline can be decreased when it is combined with Calcium lactate gluconate.Experimental
Calcium levulinateThe serum concentration of Tetracycline can be decreased when it is combined with Calcium levulinate.Approved, Experimental
Calcium pangamateThe serum concentration of Tetracycline can be decreased when it is combined with Calcium pangamate.Experimental
Calcium PhosphateThe serum concentration of Tetracycline can be decreased when it is combined with Calcium Phosphate.Approved
Calcium silicateCalcium silicate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CamazepamThe risk or severity of adverse effects can be increased when Camazepam is combined with Tetracycline.Approved, Illicit
CanagliflozinThe serum concentration of Tetracycline can be increased when it is combined with Canagliflozin.Approved
CannabidiolThe risk or severity of adverse effects can be increased when Tetracycline is combined with Cannabidiol.Approved, Investigational
CannabidivarinThe risk or severity of adverse effects can be increased when Cannabidivarin is combined with Tetracycline.Investigational
CapreomycinThe risk or severity of adverse effects can be increased when Capreomycin is combined with Tetracycline.Approved
Caprylic acidThe excretion of Tetracycline can be decreased when combined with Caprylic acid.Approved, Experimental, Investigational
CaptodiameThe risk or severity of adverse effects can be increased when Captodiame is combined with Tetracycline.Approved, Investigational
CaptoprilThe serum concentration of Tetracycline can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Tetracycline can be increased when combined with Carbamazepine.Approved, Investigational
CarbenicillinThe therapeutic efficacy of Carbenicillin can be decreased when used in combination with Tetracycline.Approved, Investigational
Carbenicillin indanylThe therapeutic efficacy of Carbenicillin indanyl can be decreased when used in combination with Tetracycline.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Tetracycline.Approved
CarbromalThe risk or severity of adverse effects can be increased when Carbromal is combined with Tetracycline.Experimental
CarfecillinThe therapeutic efficacy of Carfecillin can be decreased when used in combination with Tetracycline.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Tetracycline.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Cariprazine is combined with Tetracycline.Approved, Investigational
CarisbamateThe risk or severity of adverse effects can be increased when Carisbamate is combined with Tetracycline.Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Tetracycline.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Tetracycline.Withdrawn
CarvedilolThe serum concentration of Tetracycline can be increased when it is combined with Carvedilol.Approved, Investigational
CathinoneThe risk or severity of adverse effects can be increased when Cathinone is combined with Tetracycline.Illicit
CefacetrileThe excretion of Cefacetrile can be decreased when combined with Tetracycline.Approved
CefaclorThe excretion of Cefaclor can be decreased when combined with Tetracycline.Approved
CefadroxilThe excretion of Tetracycline can be decreased when combined with Cefadroxil.Approved, Vet Approved, Withdrawn
CefalotinThe excretion of Tetracycline can be decreased when combined with Cefalotin.Approved, Investigational, Vet Approved
CefamandoleThe excretion of Tetracycline can be decreased when combined with Cefamandole.Approved, Investigational
CefazolinThe excretion of Cefazolin can be decreased when combined with Tetracycline.Approved
CefdinirThe excretion of Cefdinir can be decreased when combined with Tetracycline.Approved
CefoperazoneThe serum concentration of Tetracycline can be increased when it is combined with Cefoperazone.Approved, Investigational
CefotaximeThe excretion of Tetracycline can be decreased when combined with Cefotaxime.Approved
CefotiamThe excretion of Cefotiam can be decreased when combined with Tetracycline.Approved, Investigational
CeftibutenThe excretion of Ceftibuten can be decreased when combined with Tetracycline.Approved, Investigational
CeftizoximeThe excretion of Ceftizoxime can be decreased when combined with Tetracycline.Approved, Investigational
CeftriaxoneThe serum concentration of Tetracycline can be increased when it is combined with Ceftriaxone.Approved
CephalexinThe excretion of Cephalexin can be decreased when combined with Tetracycline.Approved, Investigational, Vet Approved
CephaloridineThe excretion of Cephaloridine can be decreased when combined with Tetracycline.Approved, Withdrawn
CeritinibThe serum concentration of Tetracycline can be increased when it is combined with Ceritinib.Approved
CerlapirdineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Cerlapirdine.Investigational
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Tetracycline.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Tetracycline.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Tetracycline.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Tetracycline.Approved, Investigational, Withdrawn
ChloroformThe serum concentration of Tetracycline can be increased when it is combined with Chloroform.Vet Approved
ChloroquineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tetracycline.Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Chlorphenesin is combined with Tetracycline.Approved, Vet Approved, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Chlorproethazine is combined with Tetracycline.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tetracycline.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tetracycline.Approved, Investigational, Withdrawn
ChlortetracyclineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Chlortetracycline.Approved, Investigational, Vet Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Tetracycline.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Cholic AcidThe excretion of Tetracycline can be decreased when combined with Cholic Acid.Approved
CilansetronThe risk or severity of adverse effects can be increased when Tetracycline is combined with Cilansetron.Investigational
CilastatinThe excretion of Tetracycline can be decreased when combined with Cilastatin.Approved, Investigational
CimetidineThe excretion of Tetracycline can be decreased when combined with Cimetidine.Approved, Investigational
CinitaprideThe risk or severity of adverse effects can be increased when Tetracycline is combined with Cinitapride.Approved, Investigational
CinolazepamThe risk or severity of adverse effects can be increased when Cinolazepam is combined with Tetracycline.Approved
CisaprideThe risk or severity of adverse effects can be increased when Tetracycline is combined with Cisapride.Approved, Investigational, Withdrawn
CisatracuriumThe therapeutic efficacy of Cisatracurium can be increased when used in combination with Tetracycline.Approved
CitalopramThe risk or severity of adverse effects can be increased when Tetracycline is combined with Citalopram.Approved
ClarithromycinThe metabolism of Tetracycline can be decreased when combined with Clarithromycin.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Tetracycline.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Tetracycline.Approved
ClindamycinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Tetracycline.Approved, Vet Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Tetracycline.Approved, Illicit
ClofazimineThe serum concentration of Tetracycline can be increased when it is combined with Clofazimine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Tetracycline.Investigational
ClometocillinThe therapeutic efficacy of Clometocillin can be decreased when used in combination with Tetracycline.Experimental
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Tetracycline.Approved, Investigational, Vet Approved
ClomocyclineThe risk or severity of adverse effects can be increased when Clomocycline is combined with Tetracycline.Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Tetracycline.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Tetracycline.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Tetracycline.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tetracycline.Approved, Illicit
ClorindioneTetracycline may increase the anticoagulant activities of Clorindione.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Tetracycline.Experimental
ClotiazepamThe risk or severity of adverse effects can be increased when Clotiazepam is combined with Tetracycline.Approved, Illicit
ClotrimazoleThe metabolism of Tetracycline can be decreased when combined with Clotrimazole.Approved, Vet Approved
CloxacillinThe therapeutic efficacy of Cloxacillin can be decreased when used in combination with Tetracycline.Approved, Investigational, Vet Approved
CloxazolamThe risk or severity of adverse effects can be increased when Cloxazolam is combined with Tetracycline.Approved, Investigational
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Tetracycline.Approved
CobicistatThe metabolism of Tetracycline can be decreased when combined with Cobicistat.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Tetracycline.Approved, Illicit
ColchicineThe serum concentration of Tetracycline can be increased when it is combined with Colchicine.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColistimethateThe risk or severity of adverse effects can be increased when Colistimethate is combined with Tetracycline.Approved, Vet Approved
ColistinThe risk or severity of adverse effects can be increased when Colistin is combined with Tetracycline.Approved
Concanamycin AThe serum concentration of Tetracycline can be increased when it is combined with Concanamycin A.Experimental
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Tetracycline.Approved, Investigational
Conjugated estrogensThe excretion of Conjugated estrogens can be decreased when combined with Tetracycline.Approved
CrizotinibThe serum concentration of Tetracycline can be increased when it is combined with Crizotinib.Approved
CurcuminThe metabolism of Tetracycline can be decreased when combined with Curcumin.Approved, Investigational
CyamemazineThe risk or severity of adverse effects can be increased when Cyamemazine is combined with Tetracycline.Approved
CyclacillinThe therapeutic efficacy of Cyclacillin can be decreased when used in combination with Tetracycline.Approved
Cyclic Adenosine MonophosphateThe excretion of Cyclic Adenosine Monophosphate can be decreased when combined with Tetracycline.Experimental
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Tetracycline.Approved
CyclobarbitalThe risk or severity of adverse effects can be increased when Cyclobarbital is combined with Tetracycline.Experimental
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tetracycline.Approved
CyclopentamineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Cyclopentamine.Withdrawn
CyclopropaneThe risk or severity of adverse effects can be increased when Cyclopropane is combined with Tetracycline.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Tetracycline.Approved
DabrafenibThe serum concentration of Tetracycline can be decreased when it is combined with Dabrafenib.Approved, Investigational
DaclatasvirThe serum concentration of Tetracycline can be increased when it is combined with Daclatasvir.Approved, Investigational
DactinomycinThe serum concentration of Tetracycline can be increased when it is combined with Dactinomycin.Approved, Investigational
DanazolThe metabolism of Tetracycline can be decreased when combined with Danazol.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Tetracycline.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tetracycline.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Dapoxetine.Investigational
DarunavirThe metabolism of Tetracycline can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Tetracycline can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Tetracycline can be increased when it is combined with Daunorubicin.Approved
DeanolThe risk or severity of adverse effects can be increased when Deanol is combined with Tetracycline.Experimental
DecamethoniumThe therapeutic efficacy of Decamethonium can be increased when used in combination with Tetracycline.Approved
DeferasiroxThe serum concentration of Tetracycline can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Tetracycline can be decreased when combined with Delavirdine.Approved
DelorazepamThe risk or severity of adverse effects can be increased when Delorazepam is combined with Tetracycline.Approved, Illicit, Investigational
DemeclocyclineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Demeclocycline.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Tetracycline.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Tetracycline.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Tetracycline.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Tetracycline.Approved, Investigational
DesmethylsertralineThe serum concentration of Tetracycline can be increased when it is combined with Desmethylsertraline.Experimental
DesvenlafaxineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Tetracycline.Vet Approved
DexamethasoneThe serum concentration of Tetracycline can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tetracycline.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tetracycline.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Tetracycline is combined with Dexmethylphenidate.Approved, Investigational
DexniguldipineThe serum concentration of Tetracycline can be increased when it is combined with Dexniguldipine.Experimental
DextofisopamThe risk or severity of adverse effects can be increased when Dextofisopam is combined with Tetracycline.Investigational
DextromethorphanThe risk or severity of adverse effects can be increased when Tetracycline is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Tetracycline.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tetracycline.Approved, Illicit, Investigational, Withdrawn
DexverapamilThe serum concentration of Tetracycline can be increased when it is combined with Dexverapamil.Experimental
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Tetracycline.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Tetracycline.Approved, Illicit, Investigational, Vet Approved
DibekacinThe risk or severity of adverse effects can be increased when Tetracycline is combined with Dibekacin.Experimental
DibenzepinThe risk or severity of adverse effects can be increased when Dibenzepin is combined with Tetracycline.Experimental
DichloralphenazoneThe risk or severity of adverse effects can be increased when Dichloralphenazone is combined with Tetracycline.Approved, Illicit
DiclofenacThe excretion of Tetracycline can be decreased when combined with Diclofenac.Approved, Vet Approved
DicloxacillinThe therapeutic efficacy of Dicloxacillin can be decreased when used in combination with Tetracycline.Approved, Investigational, Vet Approved
DicoumarolTetracycline may increase the anticoagulant activities of Dicoumarol.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Tetracycline.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Tetracycline.Approved, Illicit
DigoxinThe excretion of Tetracycline can be decreased when combined with Digoxin.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tetracycline.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Dihydroergotamine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Tetracycline.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tetracycline.Experimental, Illicit
DihydrostreptomycinThe risk or severity of adverse effects can be increased when Tetracycline is combined with Dihydrostreptomycin.Investigational, Vet Approved
DiltiazemThe metabolism of Tetracycline can be decreased when combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Tetracycline.Approved
DimetacrineThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Tetracycline.Approved, Withdrawn
DimethyltryptamineThe risk or severity of adverse effects can be increased when Dimethyltryptamine is combined with Tetracycline.Experimental, Illicit
DinoprostoneThe excretion of Dinoprostone can be decreased when combined with Tetracycline.Approved
DiphenadioneTetracycline may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tetracycline.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tetracycline.Approved, Illicit
DipyridamoleThe serum concentration of Tetracycline can be increased when it is combined with Dipyridamole.Approved
Ditiocarb ZincDitiocarb Zinc can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Tetracycline.Experimental
DofequidarThe serum concentration of Tetracycline can be increased when it is combined with Dofequidar.Experimental, Investigational
DolasetronThe risk or severity of adverse effects can be increased when Tetracycline is combined with Dolasetron.Approved, Investigational
DolutegravirThe excretion of Tetracycline can be decreased when combined with Dolutegravir.Approved
Domoic AcidThe risk or severity of adverse effects can be increased when Domoic Acid is combined with Tetracycline.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Donepezil is combined with Tetracycline.Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Tetracycline.Vet Approved
DosulepinThe risk or severity of adverse effects can be increased when Dosulepin is combined with Tetracycline.Approved
DotarizineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Dotarizine.Investigational
DovitinibThe serum concentration of Tetracycline can be increased when it is combined with Dovitinib.Investigational
DoxacuriumThe therapeutic efficacy of Doxacurium can be increased when used in combination with Tetracycline.Approved
DoxazosinThe serum concentration of Tetracycline can be increased when it is combined with Doxazosin.Approved
DoxefazepamThe risk or severity of adverse effects can be increased when Doxefazepam is combined with Tetracycline.Experimental
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Tetracycline.Approved, Investigational
DoxycyclineThe metabolism of Tetracycline can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Tetracycline.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Tetracycline.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Tetracycline.Approved, Illicit
DronedaroneThe serum concentration of Tetracycline can be increased when it is combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tetracycline.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Tetracycline.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tetracycline.Approved
EconazoleThe serum concentration of Tetracycline can be increased when it is combined with Econazole.Approved
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Tetracycline.Investigational
EdaravoneThe excretion of Edaravone can be decreased when combined with Tetracycline.Approved, Investigational
EdivoxetineThe risk or severity of adverse effects can be increased when Edivoxetine is combined with Tetracycline.Investigational
EfavirenzThe metabolism of Tetracycline can be decreased when combined with Efavirenz.Approved, Investigational
ElacridarThe serum concentration of Tetracycline can be increased when it is combined with Elacridar.Investigational
EletriptanThe risk or severity of adverse effects can be increased when Tetracycline is combined with Eletriptan.Approved, Investigational
Ellagic AcidThe excretion of Ellagic Acid can be decreased when combined with Tetracycline.Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Tetracycline.Investigational
EltoprazineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Eltoprazine.Investigational
EluxadolineThe excretion of Eluxadoline can be decreased when combined with Tetracycline.Approved, Investigational
EmeproniumThe risk or severity of adverse effects can be increased when Emepronium is combined with Tetracycline.Experimental
EmopamilThe serum concentration of Tetracycline can be increased when it is combined with Emopamil.Experimental
EmylcamateThe risk or severity of adverse effects can be increased when Emylcamate is combined with Tetracycline.Experimental
EnalaprilThe excretion of Tetracycline can be decreased when combined with Enalapril.Approved, Vet Approved
EnasidenibThe serum concentration of Tetracycline can be increased when it is combined with Enasidenib.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Tetracycline.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Tetracycline.Approved, Investigational
EnzalutamideThe serum concentration of Tetracycline can be decreased when it is combined with Enzalutamide.Approved
EperisoneThe risk or severity of adverse effects can be increased when Eperisone is combined with Tetracycline.Approved, Investigational
EpicillinThe therapeutic efficacy of Epicillin can be decreased when used in combination with Tetracycline.Experimental
EpinastineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Epinastine.Approved, Investigational
EplivanserinThe risk or severity of adverse effects can be increased when Tetracycline is combined with Eplivanserin.Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Tetracycline is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Tetracycline can be increased when it is combined with Erlotinib.Approved, Investigational
ErythromycinThe serum concentration of Tetracycline can be increased when it is combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Tetracycline is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Tetracycline.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Esmirtazapine is combined with Tetracycline.Investigational
EsomeprazoleThe serum concentration of Tetracycline can be increased when it is combined with Esomeprazole.Approved, Investigational
EsreboxetineThe risk or severity of adverse effects can be increased when Esreboxetine is combined with Tetracycline.Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Tetracycline.Approved, Illicit
EstradiolThe excretion of Estradiol can be decreased when combined with Tetracycline.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Tetracycline can be increased when it is combined with Estramustine.Approved, Investigational
EstroneThe excretion of Estrone can be decreased when combined with Tetracycline.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Tetracycline.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Tetracycline is combined with Etacrynic acid.Approved, Investigational
EthadioneThe risk or severity of adverse effects can be increased when Ethadione is combined with Tetracycline.Experimental
EthanolTetracycline may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tetracycline.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tetracycline.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Tetracycline.Approved
Ethyl biscoumacetateTetracycline may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tetracycline.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Tetracycline.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Tetracycline.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Tetracycline.Approved, Illicit
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Tetracycline.Investigational, Withdrawn
EtiracetamThe risk or severity of adverse effects can be increased when Etiracetam is combined with Tetracycline.Investigational
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Tetracycline.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Tetracycline.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Etoperidone is combined with Tetracycline.Withdrawn
EtoposideThe serum concentration of Tetracycline can be increased when it is combined with Etoposide.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Tetracycline.Illicit, Vet Approved
EtravirineThe serum concentration of Tetracycline can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Tetracycline.Approved, Investigational
FabomotizoleThe risk or severity of adverse effects can be increased when Fabomotizole is combined with Tetracycline.Experimental
FamotidineThe excretion of Famotidine can be decreased when combined with Tetracycline.Approved
Fazadinium bromideThe risk or severity of adverse effects can be increased when Fazadinium bromide is combined with Tetracycline.Experimental
FebarbamateThe risk or severity of adverse effects can be increased when Febarbamate is combined with Tetracycline.Experimental
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Tetracycline.Approved
FelodipineThe serum concentration of Tetracycline can be increased when it is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Tetracycline.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FenofibrateThe serum concentration of Tetracycline can be increased when it is combined with Fenofibrate.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tetracycline.Approved, Illicit, Investigational, Vet Approved
FenyramidolThe risk or severity of adverse effects can be increased when Fenyramidol is combined with Tetracycline.Experimental
Ferric ammonium citrateTetracycline can cause a decrease in the absorption of Ferric ammonium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric CarboxymaltoseTetracycline can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric cationTetracycline can cause a decrease in the absorption of Ferric cation resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric hydroxideTetracycline can cause a decrease in the absorption of Ferric hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ferric oxideTetracycline can cause a decrease in the absorption of Ferric oxide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric pyrophosphateTetracycline can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ferric subsulfateTetracycline can cause a decrease in the absorption of Ferric subsulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Ferric sulfateTetracycline can cause a decrease in the absorption of Ferric sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous bisglycinateTetracycline can cause a decrease in the absorption of Ferrous bisglycinate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous chlorideTetracycline can cause a decrease in the absorption of Ferrous chloride resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ferrous fumarateTetracycline can cause a decrease in the absorption of Ferrous fumarate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous gluconateTetracycline can cause a decrease in the absorption of Ferrous gluconate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous succinateTetracycline can cause a decrease in the absorption of Ferrous succinate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous sulfateTetracycline can cause a decrease in the absorption of Ferrous sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
FerumoxidesTetracycline can cause a decrease in the absorption of Ferumoxides resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FerumoxsilTetracycline can cause a decrease in the absorption of Ferumoxsil resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FerumoxytolTetracycline can cause a decrease in the absorption of Ferumoxytol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Tetracycline.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Tetracycline.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Tetracycline.Experimental
FlucloxacillinThe therapeutic efficacy of Flucloxacillin can be decreased when used in combination with Tetracycline.Approved, Investigational
FluconazoleThe serum concentration of Tetracycline can be increased when it is combined with Fluconazole.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Tetracycline.Approved, Illicit
FluindioneTetracycline may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Tetracycline.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Tetracycline.Approved, Illicit
FluoresceinThe excretion of Fluorescein can be decreased when combined with Tetracycline.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Tetracycline.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Tetracycline.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Tetracycline.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Tetracycline.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Tetracycline.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Tetracycline can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Tetracycline can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Tetracycline can be increased when combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Tetracycline.Approved, Illicit, Investigational
FramycetinThe risk or severity of adverse effects can be increased when Tetracycline is combined with Framycetin.Approved
FrovatriptanThe risk or severity of adverse effects can be increased when Tetracycline is combined with Frovatriptan.Approved, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Tetracycline.Approved, Investigational, Vet Approved
FurosemideThe excretion of Tetracycline can be decreased when combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Tetracycline can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tetracycline.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Tetracycline.Approved, Investigational
GaboxadolThe risk or severity of adverse effects can be increased when Gaboxadol is combined with Tetracycline.Investigational
GallamineThe therapeutic efficacy of Gallamine can be increased when used in combination with Tetracycline.Experimental
Gallamine TriethiodideThe therapeutic efficacy of Gallamine Triethiodide can be increased when used in combination with Tetracycline.Approved
GallopamilThe serum concentration of Tetracycline can be increased when it is combined with Gallopamil.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Tetracycline.Approved, Illicit, Investigational
GanciclovirThe excretion of Tetracycline can be decreased when combined with Ganciclovir.Approved, Investigational
Gantacurium ChlorideThe risk or severity of adverse effects can be increased when Gantacurium Chloride is combined with Tetracycline.Investigational
GedocarnilThe risk or severity of adverse effects can be increased when Gedocarnil is combined with Tetracycline.Experimental
GefitinibThe serum concentration of Tetracycline can be increased when it is combined with Gefitinib.Approved, Investigational
GeneticinThe risk or severity of adverse effects can be increased when Tetracycline is combined with Geneticin.Experimental
GenisteinThe serum concentration of Tetracycline can be increased when it is combined with Genistein.Investigational
GentamicinThe risk or severity of adverse effects can be increased when Tetracycline is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of adverse effects can be increased when Tetracycline is combined with GENTAMICIN C1A.Experimental
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Tetracycline.Investigational
GlecaprevirThe serum concentration of Tetracycline can be increased when it is combined with Glecaprevir.Approved, Investigational
GleptoferronTetracycline can cause a decrease in the absorption of Gleptoferron resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
Glutaric AcidThe excretion of Tetracycline can be decreased when combined with Glutaric Acid.Experimental
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Tetracycline.Approved, Illicit
GlyburideThe serum concentration of Tetracycline can be increased when it is combined with Glyburide.Approved
GlycerinThe serum concentration of Tetracycline can be increased when it is combined with Glycerin.Approved, Investigational
Gramicidin DThe serum concentration of Tetracycline can be increased when it is combined with Gramicidin D.Approved
GranisetronThe risk or severity of adverse effects can be increased when Tetracycline is combined with Granisetron.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Tetracycline.Approved, Investigational
GuanidineThe excretion of Tetracycline can be decreased when combined with Guanidine.Approved
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Tetracycline.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Tetracycline.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Tetracycline.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Harmaline is combined with Tetracycline.Experimental
HeptabarbitalThe risk or severity of adverse effects can be increased when Heptabarbital is combined with Tetracycline.Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Tetracycline.Approved, Illicit, Investigational
HetacillinThe therapeutic efficacy of Hetacillin can be decreased when used in combination with Tetracycline.Approved, Vet Approved, Withdrawn
HexafluroniumThe risk or severity of adverse effects can be increased when Hexafluronium is combined with Tetracycline.Approved
HexamethoniumThe risk or severity of adverse effects can be increased when Tetracycline is combined with Hexamethonium.Experimental
HexapropymateThe risk or severity of adverse effects can be increased when Hexapropymate is combined with Tetracycline.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Tetracycline.Approved
HM-30181The serum concentration of Tetracycline can be increased when it is combined with HM-30181.Experimental
HycanthoneThe serum concentration of Tetracycline can be increased when it is combined with Hycanthone.Approved, Investigational
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Tetracycline.Experimental
HydrocodoneTetracycline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe excretion of Hydrocortisone can be decreased when combined with Tetracycline.Approved, Vet Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Tetracycline.Approved, Illicit
HydrotalciteHydrotalcite can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational
HydroxychloroquineThe serum concentration of Tetracycline can be increased when it is combined with Hydroxychloroquine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tetracycline.Approved
Hygromycin BThe risk or severity of adverse effects can be increased when Tetracycline is combined with Hygromycin B.Vet Approved
HypericinThe risk or severity of adverse effects can be increased when Hypericin is combined with Tetracycline.Investigational
IbuprofenThe serum concentration of Tetracycline can be increased when it is combined with Ibuprofen.Approved
IdalopirdineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Idalopirdine.Investigational
IdelalisibThe metabolism of Tetracycline can be decreased when combined with Idelalisib.Approved
IfenprodilThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Tetracycline.Approved, Investigational, Withdrawn
IferanserinThe risk or severity of adverse effects can be increased when Tetracycline is combined with Iferanserin.Investigational
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Tetracycline.Approved
ImagabalinThe risk or severity of adverse effects can be increased when Imagabalin is combined with Tetracycline.Investigational
ImatinibThe serum concentration of Tetracycline can be increased when it is combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Tetracycline.Approved
Imipramine oxideThe risk or severity of adverse effects can be increased when Imipramine oxide is combined with Tetracycline.Experimental
IndalpineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Tetracycline can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Tetracycline.Investigational
IndomethacinThe serum concentration of Tetracycline can be increased when it is combined with Indomethacin.Approved, Investigational
IprazochromeThe risk or severity of adverse effects can be increased when Tetracycline is combined with Iprazochrome.Experimental
IprindoleThe risk or severity of adverse effects can be increased when Iprindole is combined with Tetracycline.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Tetracycline.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Tetracycline.Withdrawn
IronTetracycline can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranTetracycline can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron isomaltoside 1000Tetracycline can cause a decrease in the absorption of Iron isomaltoside 1000 resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Iron saccharateThe serum concentration of Tetracycline can be decreased when it is combined with Iron saccharate.Approved
IsavuconazoleThe serum concentration of Tetracycline can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe serum concentration of Tetracycline can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsepamicinThe risk or severity of adverse effects can be increased when Tetracycline is combined with Isepamicin.Experimental
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Tetracycline.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Tetracycline.Approved, Vet Approved
IsoniazidThe metabolism of Tetracycline can be decreased when combined with Isoniazid.Approved, Investigational
IsotretinoinThe risk or severity of adverse effects can be increased when Tetracycline is combined with Isotretinoin.Approved
IsradipineThe serum concentration of Tetracycline can be increased when it is combined with Isradipine.Approved, Investigational
ItraconazoleThe metabolism of Tetracycline can be decreased when combined with Itraconazole.Approved, Investigational
IvermectinThe serum concentration of Tetracycline can be increased when it is combined with Ivermectin.Approved, Investigational, Vet Approved
IvosidenibThe serum concentration of Tetracycline can be increased when it is combined with Ivosidenib.Approved, Investigational
KanamycinThe risk or severity of adverse effects can be increased when Kanamycin is combined with Tetracycline.Approved, Investigational, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Tetracycline.Approved, Vet Approved
KetanserinThe risk or severity of adverse effects can be increased when Tetracycline is combined with Ketanserin.Investigational
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Tetracycline.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Tetracycline.Approved, Investigational
KetoconazoleThe metabolism of Tetracycline can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe excretion of Tetracycline can be decreased when combined with Ketoprofen.Approved, Vet Approved
L-CarnitineThe excretion of L-Carnitine can be decreased when combined with Tetracycline.Approved, Investigational
L-CitrullineThe excretion of L-Citrulline can be decreased when combined with Tetracycline.Approved, Investigational, Nutraceutical
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Tetracycline.Approved, Nutraceutical, Withdrawn
LacosamideThe risk or severity of adverse effects can be increased when Lacosamide is combined with Tetracycline.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tetracycline.Approved, Investigational
LanicemineThe risk or severity of adverse effects can be increased when Lanicemine is combined with Tetracycline.Investigational
LaniquidarThe serum concentration of Tetracycline can be increased when it is combined with Laniquidar.Investigational
LansoprazoleThe serum concentration of Tetracycline can be increased when it is combined with Lansoprazole.Approved, Investigational
Lanthanum carbonateThe serum concentration of Tetracycline can be decreased when it is combined with Lanthanum carbonate.Approved
LapatinibThe serum concentration of Tetracycline can be increased when it is combined with Lapatinib.Approved, Investigational
LasmiditanThe risk or severity of adverse effects can be increased when Tetracycline is combined with Lasmiditan.Investigational
LedipasvirThe serum concentration of Tetracycline can be increased when it is combined with Ledipasvir.Approved
LenvatinibThe excretion of Tetracycline can be decreased when combined with Lenvatinib.Approved, Investigational
LetermovirThe serum concentration of Tetracycline can be increased when it is combined with Letermovir.Approved, Investigational
LeucovorinThe excretion of Leucovorin can be decreased when combined with Tetracycline.Approved
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Tetracycline.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Tetracycline.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Tetracycline.Approved
LevofloxacinThe serum concentration of Tetracycline can be increased when it is combined with Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Tetracycline.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Tetracycline is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tetracycline.Approved
LidocaineThe serum concentration of Tetracycline can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Tetracycline can be increased when it is combined with Linagliptin.Approved
LincomycinThe risk or severity of adverse effects can be increased when Lincomycin is combined with Tetracycline.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Tetracycline is combined with Linezolid.Approved, Investigational
LiothyronineThe excretion of Tetracycline can be decreased when combined with Liothyronine.Approved, Vet Approved
LiotrixThe excretion of Tetracycline can be decreased when combined with Liotrix.Approved
LisurideThe risk or severity of adverse effects can be increased when Tetracycline is combined with Lisuride.Approved, Investigational
Lithium carbonateThe risk or severity of adverse effects can be increased when Tetracycline is combined with Lithium carbonate.Approved
Lithium cationThe risk or severity of adverse effects can be increased when Lithium cation is combined with Tetracycline.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Tetracycline.Illicit
LofepramineThe risk or severity of adverse effects can be increased when Lofepramine is combined with Tetracycline.Experimental
LofexidineThe therapeutic efficacy of Tetracycline can be increased when used in combination with Lofexidine.Approved, Investigational
LomerizineThe serum concentration of Tetracycline can be increased when it is combined with Lomerizine.Experimental
LomitapideThe serum concentration of Tetracycline can be increased when it is combined with Lomitapide.Approved, Investigational
LonafarnibThe serum concentration of Tetracycline can be increased when it is combined with Lonafarnib.Investigational
LoperamideThe serum concentration of Tetracycline can be increased when it is combined with Loperamide.Approved
LopinavirThe metabolism of Tetracycline can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Tetracycline.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Tetracycline.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Tetracycline.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Tetracycline is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Tetracycline.Approved
LorpiprazoleThe serum concentration of Tetracycline can be increased when it is combined with Lorpiprazole.Approved
LortalamineThe risk or severity of adverse effects can be increased when Lortalamine is combined with Tetracycline.Experimental
LosartanThe serum concentration of Tetracycline can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Tetracycline can be increased when it is combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Tetracycline.Approved
LuliconazoleThe serum concentration of Tetracycline can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Tetracycline can be decreased when it is combined with Lumacaftor.Approved
LumateperoneThe risk or severity of adverse effects can be increased when Lumateperone is combined with Tetracycline.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Tetracycline.Approved, Investigational
LusutrombopagThe serum concentration of Tetracycline can be increased when it is combined with Lusutrombopag.Approved, Investigational
LymecyclineThe risk or severity of adverse effects can be increased when Lymecycline is combined with Tetracycline.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Tetracycline.Illicit, Investigational, Withdrawn
m-ChlorophenylpiperazineThe risk or severity of adverse effects can be increased when Tetracycline is combined with m-Chlorophenylpiperazine.Investigational
MagaldrateMagaldrate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium acetateThe risk or severity of adverse effects can be increased when Tetracycline is combined with Magnesium acetate.Approved
Magnesium acetate tetrahydrateThe risk or severity of adverse effects can be increased when Tetracycline is combined with Magnesium acetate tetrahydrate.Approved
Magnesium Aluminum SilicateThe risk or severity of adverse effects can be increased when Tetracycline is combined with Magnesium Aluminum Silicate.Approved
Magnesium aspartateThe risk or severity of adverse effects can be increased when Tetracycline is combined with Magnesium aspartate.Experimental
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium cationThe risk or severity of adverse effects can be increased when Tetracycline is combined with Magnesium cation.Approved, Nutraceutical
Magnesium chlorideThe risk or severity of adverse effects can be increased when Tetracycline is combined with Magnesium chloride.Approved
Magnesium citrateThe risk or severity of adverse effects can be increased when Tetracycline is combined with Magnesium citrate.Approved
Magnesium gluconateThe risk or severity of adverse effects can be increased when Tetracycline is combined with Magnesium gluconate.Approved, Investigational
Magnesium glycinateThe risk or severity of adverse effects can be increased when Tetracycline is combined with Magnesium glycinate.Approved
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium orotateThe risk or severity of adverse effects can be increased when Tetracycline is combined with Magnesium orotate.Experimental
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium phosphateThe risk or severity of adverse effects can be increased when Tetracycline is combined with Magnesium phosphate.Experimental
Magnesium salicylateMagnesium salicylate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium stearateThe risk or severity of adverse effects can be increased when Tetracycline is combined with Magnesium stearate.Investigational
Magnesium sulfateThe therapeutic efficacy of Tetracycline can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Tetracycline.Approved, Investigational
MazindolThe risk or severity of adverse effects can be increased when Mazindol is combined with Tetracycline.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Tetracycline.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Tetracycline.Experimental
MebutamateThe risk or severity of adverse effects can be increased when Mebutamate is combined with Tetracycline.Approved
MecamylamineTetracycline may increase the neuromuscular blocking activities of Mecamylamine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Tetracycline.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Tetracycline.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Tetracycline.Vet Approved
MedifoxamineThe risk or severity of adverse effects can be increased when Medifoxamine is combined with Tetracycline.Experimental
MedrogestoneThe serum concentration of Medrogestone can be decreased when it is combined with Tetracycline.Approved
MefloquineThe serum concentration of Tetracycline can be increased when it is combined with Mefloquine.Approved, Investigational
Megestrol acetateThe serum concentration of Tetracycline can be increased when it is combined with Megestrol acetate.Approved, Investigational, Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Tetracycline.Approved, Nutraceutical, Vet Approved
MelitracenThe risk or severity of adverse effects can be increased when Melitracen is combined with Tetracycline.Experimental, Investigational
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Tetracycline.Approved, Investigational
MephenesinThe risk or severity of adverse effects can be increased when Mephenesin is combined with Tetracycline.Approved
MephenoxaloneThe risk or severity of adverse effects can be increased when Mephenoxalone is combined with Tetracycline.Experimental
MephenytoinThe risk or severity of adverse effects can be increased when Mephenytoin is combined with Tetracycline.Investigational, Withdrawn
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tetracycline.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Tetracycline.Experimental
MercaptopurineThe excretion of Mercaptopurine can be decreased when combined with Tetracycline.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Tetracycline.Approved, Investigational
MetampicillinThe therapeutic efficacy of Metampicillin can be decreased when used in combination with Tetracycline.Experimental
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Tetracycline.Approved
MetergolineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Metergoline.Experimental
MethacyclineThe risk or severity of adverse effects can be increased when Methacycline is combined with Tetracycline.Approved, Investigational
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Tetracycline.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Tetracycline.Approved, Illicit
MethamphetamineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Tetracycline.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Tetracycline.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Tetracycline.Illicit, Withdrawn
MetharbitalThe risk or severity of adverse effects can be increased when Metharbital is combined with Tetracycline.Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Tetracycline.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Tetracycline.Approved
MethotrexateThe excretion of Methotrexate can be decreased when combined with Tetracycline.Approved
MethotrimeprazineTetracycline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Tetracycline.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Tetracycline.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Tetracycline.Approved, Investigational
MethylpentynolThe risk or severity of adverse effects can be increased when Methylpentynol is combined with Tetracycline.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Tetracycline is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Tetracycline.Approved
MethyprylonThe risk or severity of adverse effects can be increased when Methyprylon is combined with Tetracycline.Approved, Illicit, Withdrawn
MethysergideThe risk or severity of adverse effects can be increased when Tetracycline is combined with Methysergide.Approved
MeticillinThe therapeutic efficacy of Meticillin can be decreased when used in combination with Tetracycline.Approved, Investigational
MetocurineThe therapeutic efficacy of Metocurine can be increased when used in combination with Tetracycline.Approved
Metocurine IodideThe therapeutic efficacy of Metocurine Iodide can be increased when used in combination with Tetracycline.Approved, Withdrawn
MetronidazoleThe serum concentration of Tetracycline can be increased when it is combined with Metronidazole.Approved
MetyrosineTetracycline may increase the sedative activities of Metyrosine.Approved
MezlocillinThe therapeutic efficacy of Mezlocillin can be decreased when used in combination with Tetracycline.Approved, Investigational
MianserinThe risk or severity of adverse effects can be increased when Mianserin is combined with Tetracycline.Approved, Investigational
MibefradilThe metabolism of Tetracycline can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Tetracycline can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MicronomicinThe risk or severity of adverse effects can be increased when Tetracycline is combined with Micronomicin.Experimental
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Tetracycline.Approved, Illicit
MidomafetamineThe risk or severity of adverse effects can be increased when Midomafetamine is combined with Tetracycline.Experimental, Illicit, Investigational
MifepristoneThe serum concentration of Tetracycline can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Tetracycline is combined with Milnacipran.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Tetracycline.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tetracycline.Approved, Investigational
MipomersenTetracycline may increase the hepatotoxic activities of Mipomersen.Approved, Investigational
MirtazapineTetracycline may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Tetracycline can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Tetracycline can be increased when it is combined with Mitoxantrone.Approved, Investigational
MivacuriumThe therapeutic efficacy of Mivacurium can be increased when used in combination with Tetracycline.Approved
MK-212The risk or severity of adverse effects can be increased when Tetracycline is combined with MK-212.Investigational
MMDAThe risk or severity of adverse effects can be increased when Tetracycline is combined with MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Tetracycline.Approved, Investigational
ModafinilThe serum concentration of Tetracycline can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Tetracycline.Approved
MonensinThe serum concentration of Tetracycline can be increased when it is combined with Monensin.Vet Approved
MoperoneThe risk or severity of adverse effects can be increased when Moperone is combined with Tetracycline.Experimental
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Tetracycline.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Tetracycline.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Mosapramine is combined with Tetracycline.Experimental
MosaprideThe risk or severity of adverse effects can be increased when Tetracycline is combined with Mosapride.Investigational
MRK-409The risk or severity of adverse effects can be increased when MRK-409 is combined with Tetracycline.Experimental
N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamineThe risk or severity of adverse effects can be increased when Tetracycline is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Tetracycline.Approved, Investigational
NafcillinThe therapeutic efficacy of Nafcillin can be decreased when used in combination with Tetracycline.Approved, Investigational
NaftidrofurylThe risk or severity of adverse effects can be increased when Tetracycline is combined with Naftidrofuryl.Experimental
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Tetracycline.Approved
NaloxoneThe metabolism of Tetracycline can be decreased when combined with Naloxone.Approved, Vet Approved
NaluzotanThe risk or severity of adverse effects can be increased when Tetracycline is combined with Naluzotan.Investigational
NaratriptanThe risk or severity of adverse effects can be increased when Tetracycline is combined with Naratriptan.Approved, Investigational
NaronaprideThe risk or severity of adverse effects can be increased when Tetracycline is combined with Naronapride.Investigational
NeamineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Neamine.Experimental
NefazodoneThe risk or severity of adverse effects can be increased when Tetracycline is combined with Nefazodone.Approved, Withdrawn
NefiracetamThe risk or severity of adverse effects can be increased when Nefiracetam is combined with Tetracycline.Investigational
NelfinavirThe metabolism of Tetracycline can be decreased when combined with Nelfinavir.Approved
NeocitrullamonThe risk or severity of adverse effects can be increased when Neocitrullamon is combined with Tetracycline.Experimental
NeomycinThe risk or severity of adverse effects can be increased when Tetracycline is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinThe therapeutic efficacy of Neosaxitoxin can be increased when used in combination with Tetracycline.Investigational
NeratinibThe serum concentration of Tetracycline can be increased when it is combined with Neratinib.Approved, Investigational
NetilmicinThe risk or severity of adverse effects can be increased when Tetracycline is combined with Netilmicin.Approved, Investigational
NetupitantThe serum concentration of Tetracycline can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Tetracycline can be increased when combined with Nevirapine.Approved
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Tetracycline.Withdrawn
NiaprazineThe risk or severity of adverse effects can be increased when Niaprazine is combined with Tetracycline.Experimental
NicardipineThe serum concentration of Tetracycline can be increased when it is combined with Nicardipine.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Nicotine.Approved
NigericinThe serum concentration of Tetracycline can be increased when it is combined with Nigericin.Experimental
NiguldipineThe serum concentration of Tetracycline can be increased when it is combined with Niguldipine.Experimental
NilotinibThe metabolism of Tetracycline can be decreased when combined with Nilotinib.Approved, Investigational
NimodipineThe serum concentration of Tetracycline can be increased when it is combined with Nimodipine.Approved, Investigational
NisoldipineThe serum concentration of Tetracycline can be increased when it is combined with Nisoldipine.Approved
NisoxetineThe risk or severity of adverse effects can be increased when Nisoxetine is combined with Tetracycline.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Tetracycline.Approved
NitrendipineThe serum concentration of Tetracycline can be increased when it is combined with Nitrendipine.Approved, Investigational
NitroprussideTetracycline can cause a decrease in the absorption of Nitroprusside resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Tetracycline.Approved, Vet Approved
NomifensineThe risk or severity of adverse effects can be increased when Nomifensine is combined with Tetracycline.Withdrawn
NordazepamThe risk or severity of adverse effects can be increased when Nordazepam is combined with Tetracycline.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Tetracycline.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Tetracycline.Approved
NovobiocinThe excretion of Tetracycline can be decreased when combined with Novobiocin.Approved, Investigational, Vet Approved
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Tetracycline.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Tetracycline.Approved, Investigational
OlaparibThe metabolism of Tetracycline can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tetracycline.Approved
OmeprazoleThe serum concentration of Tetracycline can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Tetracycline.Approved
ONT-093The serum concentration of Tetracycline can be increased when it is combined with ONT-093.Investigational
OpipramolThe risk or severity of adverse effects can be increased when Opipramol is combined with Tetracycline.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Tetracycline.Approved, Illicit
OrphenadrineTetracycline may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OrvepitantThe risk or severity of adverse effects can be increased when Orvepitant is combined with Tetracycline.Investigational
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Tetracycline.Investigational
OseltamivirThe excretion of Oseltamivir can be decreased when combined with Tetracycline.Approved
OsimertinibThe serum concentration of Tetracycline can be increased when it is combined with Osimertinib.Approved
OuabainThe excretion of Tetracycline can be decreased when combined with Ouabain.Approved
OxacillinThe therapeutic efficacy of Oxacillin can be decreased when used in combination with Tetracycline.Approved, Investigational
OxaflozaneThe risk or severity of adverse effects can be increased when Oxaflozane is combined with Tetracycline.Experimental
Oxalic AcidThe excretion of Oxalic Acid can be decreased when combined with Tetracycline.Experimental
OxaprotilineThe risk or severity of adverse effects can be increased when Oxaprotiline is combined with Tetracycline.Experimental
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Tetracycline.Approved
OxcarbazepineThe risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Tetracycline.Approved
OxiracetamThe risk or severity of adverse effects can be increased when Oxiracetam is combined with Tetracycline.Experimental
OxitriptanThe risk or severity of adverse effects can be increased when Oxitriptan is combined with Tetracycline.Approved, Investigational, Nutraceutical
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Tetracycline.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tetracycline.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tetracycline.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Oxypertine is combined with Tetracycline.Experimental
OxytetracyclineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Oxytetracycline.Approved, Investigational, Vet Approved
PaclitaxelThe serum concentration of Tetracycline can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Tetracycline can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Tetracycline.Approved
PalonosetronThe risk or severity of adverse effects can be increased when Tetracycline is combined with Palonosetron.Approved, Investigational
PancuroniumThe therapeutic efficacy of Pancuronium can be increased when used in combination with Tetracycline.Approved
PantoprazoleThe serum concentration of Tetracycline can be increased when it is combined with Pantoprazole.Approved
ParaldehydeTetracycline may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParamethadioneThe risk or severity of adverse effects can be increased when Paramethadione is combined with Tetracycline.Approved
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Tetracycline.Approved
ParitaprevirThe serum concentration of Tetracycline can be increased when it is combined with Paritaprevir.Approved, Investigational
ParomomycinThe risk or severity of adverse effects can be increased when Tetracycline is combined with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Paroxetine.Approved, Investigational
PenamecillinThe therapeutic efficacy of Penamecillin can be decreased when used in combination with Tetracycline.Experimental
PenbutololThe risk or severity of adverse effects can be increased when Tetracycline is combined with Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Tetracycline.Experimental
PenimepicyclineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Penimepicycline.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tetracycline.Approved, Vet Approved
PentobarbitalThe metabolism of Tetracycline can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Tetracycline is combined with Pentolinium.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Tetracycline.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Tetracycline.Approved, Investigational
PerflubutaneTetracycline can cause a decrease in the absorption of Perflubutane resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PergolideThe risk or severity of adverse effects can be increased when Tetracycline is combined with Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Tetracycline.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Tetracycline.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Tetracycline.Approved
PhenacemideThe risk or severity of adverse effects can be increased when Phenacemide is combined with Tetracycline.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Tetracycline.Experimental
PhencyclidineThe risk or severity of adverse effects can be increased when Phencyclidine is combined with Tetracycline.Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Tetracycline.Approved
PhenethylamineThe risk or severity of adverse effects can be increased when Phenethylamine is combined with Tetracycline.Experimental
PheneticillinThe therapeutic efficacy of Pheneticillin can be decreased when used in combination with Tetracycline.Approved
PheneturideThe risk or severity of adverse effects can be increased when Pheneturide is combined with Tetracycline.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Tetracycline.Experimental
PhenindioneTetracycline may increase the anticoagulant activities of Phenindione.Approved, Investigational
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Tetracycline.Withdrawn
PhenobarbitalThe metabolism of Tetracycline can be increased when combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Tetracycline.Experimental
PhenoxymethylpenicillinThe therapeutic efficacy of Phenoxymethylpenicillin can be decreased when used in combination with Tetracycline.Approved, Vet Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Tetracycline.Withdrawn
PhenprobamateThe risk or severity of adverse effects can be increased when Phenprobamate is combined with Tetracycline.Experimental
PhenprocoumonTetracycline may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhensuximideThe risk or severity of adverse effects can be increased when Phensuximide is combined with Tetracycline.Approved
PhentermineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Phentermine.Approved, Illicit
PhenylbutazoneThe excretion of Tetracycline can be decreased when combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe metabolism of Tetracycline can be increased when combined with Phenytoin.Approved, Vet Approved
PibrentasvirThe serum concentration of Tetracycline can be increased when it is combined with Pibrentasvir.Approved, Investigational
PiclozotanThe risk or severity of adverse effects can be increased when Tetracycline is combined with Piclozotan.Investigational
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Tetracycline.Approved
PimavanserinThe risk or severity of adverse effects can be increased when Pimavanserin is combined with Tetracycline.Approved, Investigational
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Tetracycline.Approved
PinazepamThe risk or severity of adverse effects can be increased when Pinazepam is combined with Tetracycline.Experimental
PindololThe risk or severity of adverse effects can be increased when Tetracycline is combined with Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Tetracycline.Approved, Investigational
PipecuroniumThe therapeutic efficacy of Pipecuronium can be increased when used in combination with Tetracycline.Approved
PiperacillinThe therapeutic efficacy of Piperacillin can be decreased when used in combination with Tetracycline.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Tetracycline.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Tetracycline.Approved, Investigational
PirlimycinThe risk or severity of adverse effects can be increased when Pirlimycin is combined with Tetracycline.Vet Approved
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Tetracycline.Approved
PiroxicamThe excretion of Tetracycline can be decreased when combined with Piroxicam.Approved, Investigational
PitolisantThe serum concentration of Tetracycline can be decreased when it is combined with Pitolisant.Approved, Investigational
PivagabineThe risk or severity of adverse effects can be increased when Pivagabine is combined with Tetracycline.Investigational
PivampicillinThe therapeutic efficacy of Pivampicillin can be decreased when used in combination with Tetracycline.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Tetracycline.Withdrawn
PivmecillinamThe therapeutic efficacy of Pivmecillinam can be decreased when used in combination with Tetracycline.Approved
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Tetracycline.Approved
PlazomicinThe risk or severity of adverse effects can be increased when Tetracycline is combined with Plazomicin.Approved, Investigational
PolaprezincPolaprezinc can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Tetracycline is combined with Polymyxin B Sulfate.Approved, Vet Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Tetracycline.Approved
PonatinibThe serum concentration of Tetracycline can be increased when it is combined with Ponatinib.Approved, Investigational
PosaconazoleThe metabolism of Tetracycline can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleTetracycline may increase the sedative activities of Pramipexole.Approved, Investigational
PravastatinThe excretion of Pravastatin can be decreased when combined with Tetracycline.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Tetracycline.Approved, Illicit
PrazosinThe serum concentration of Tetracycline can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Tetracycline can be increased when it is combined with Prednisone.Approved, Vet Approved
PregabalinThe therapeutic efficacy of Tetracycline can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PridinolThe risk or severity of adverse effects can be increased when Pridinol is combined with Tetracycline.Experimental
PrimaquineThe serum concentration of Tetracycline can be increased when it is combined with Primaquine.Approved
PrimidoneThe metabolism of Tetracycline can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe excretion of Tetracycline can be decreased when combined with Probenecid.Approved, Investigational
ProcainamideThe risk or severity of adverse effects can be increased when Tetracycline is combined with Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Tetracycline.Approved, Investigational, Vet Approved
Procaine benzylpenicillinThe therapeutic efficacy of Procaine benzylpenicillin can be decreased when used in combination with Tetracycline.Approved, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Tetracycline.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tetracycline.Approved, Vet Approved
ProgabideThe risk or severity of adverse effects can be increased when Progabide is combined with Tetracycline.Approved, Investigational
ProgesteroneThe serum concentration of Tetracycline can be increased when it is combined with Progesterone.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Tetracycline.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Tetracycline.Approved, Investigational
PropafenoneThe serum concentration of Tetracycline can be increased when it is combined with Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Tetracycline.Experimental
PropericiazineThe risk or severity of adverse effects can be increased when Propericiazine is combined with Tetracycline.Approved, Investigational
PropicillinThe therapeutic efficacy of Propicillin can be decreased when used in combination with Tetracycline.Experimental
PropiomazineThe risk or severity of adverse effects can be increased when Propiomazine is combined with Tetracycline.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Propiopromazine is combined with Tetracycline.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Tetracycline.Approved, Investigational, Vet Approved
ProthipendylThe risk or severity of adverse effects can be increased when Prothipendyl is combined with Tetracycline.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Tetracycline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Tetracycline.Experimental
Prussian blueTetracycline can cause a decrease in the absorption of Prussian blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PRX-08066The risk or severity of adverse effects can be increased when Tetracycline is combined with PRX-08066.Investigational
PsilocybineThe risk or severity of adverse effects can be increased when Psilocybine is combined with Tetracycline.Investigational
PuromycinThe risk or severity of adverse effects can be increased when Tetracycline is combined with Puromycin.Experimental
PyrantelThe therapeutic efficacy of Pyrantel can be increased when used in combination with Tetracycline.Approved, Vet Approved
PyrithyldioneThe risk or severity of adverse effects can be increased when Pyrithyldione is combined with Tetracycline.Experimental
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Tetracycline.Approved, Illicit
QuercetinThe serum concentration of Tetracycline can be increased when it is combined with Quercetin.Experimental, Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tetracycline.Approved
QuinacrineThe serum concentration of Tetracycline can be increased when it is combined with Quinacrine.Approved, Investigational
QuinaprilQuinapril can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
QuinidineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Quinidine.Approved, Investigational
QuinineThe serum concentration of Quinine can be increased when it is combined with Tetracycline.Approved
QuinupramineThe risk or severity of adverse effects can be increased when Quinupramine is combined with Tetracycline.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Tetracycline.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Tetracycline.Approved, Investigational
RamosetronThe risk or severity of adverse effects can be increased when Tetracycline is combined with Ramosetron.Approved, Investigational
RanitidineThe serum concentration of Tetracycline can be increased when it is combined with Ranitidine.Approved
RapacuroniumThe therapeutic efficacy of Rapacuronium can be increased when used in combination with Tetracycline.Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Tetracycline.Approved
ReboxetineThe risk or severity of adverse effects can be increased when Reboxetine is combined with Tetracycline.Approved, Investigational
RegorafenibThe serum concentration of Tetracycline can be increased when it is combined with Regorafenib.Approved
RemacemideThe risk or severity of adverse effects can be increased when Remacemide is combined with Tetracycline.Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tetracycline.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Tetracycline.Approved, Withdrawn
RenzaprideThe risk or severity of adverse effects can be increased when Tetracycline is combined with Renzapride.Investigational
RepinotanThe risk or severity of adverse effects can be increased when Tetracycline is combined with Repinotan.Investigational
ReposalThe risk or severity of adverse effects can be increased when Reposal is combined with Tetracycline.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Tetracycline.Approved, Investigational
Reversin 121The serum concentration of Tetracycline can be increased when it is combined with Reversin 121.Experimental
RibostamycinThe risk or severity of adverse effects can be increased when Tetracycline is combined with Ribostamycin.Approved, Investigational
RifampicinThe metabolism of Tetracycline can be increased when combined with Rifampicin.Approved
RifamycinThe metabolism of Tetracycline can be increased when combined with Rifamycin.Investigational
RifapentineThe metabolism of Tetracycline can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe metabolism of Tetracycline can be increased when combined with Rifaximin.Approved, Investigational
RilpivirineThe serum concentration of Tetracycline can be increased when it is combined with Rilpivirine.Approved
RiluzoleThe risk or severity of adverse effects can be increased when Riluzole is combined with Tetracycline.Approved, Investigational
RimexoloneThe metabolism of Tetracycline can be increased when combined with Rimexolone.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Tetracycline.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Tetracycline is combined with Ritanserin.Investigational
RitonavirThe metabolism of Tetracycline can be decreased when combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Tetracycline is combined with Rizatriptan.Approved
RocuroniumThe therapeutic efficacy of Rocuronium can be increased when used in combination with Tetracycline.Approved
RolapitantThe serum concentration of Tetracycline can be increased when it is combined with Rolapitant.Approved, Investigational
RolipramThe risk or severity of adverse effects can be increased when Rolipram is combined with Tetracycline.Investigational
RolitetracyclineThe risk or severity of adverse effects can be increased when Rolitetracycline is combined with Tetracycline.Approved
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Tetracycline.Vet Approved
RopiniroleTetracycline may increase the sedative activities of Ropinirole.Approved, Investigational
RosuvastatinThe excretion of Rosuvastatin can be decreased when combined with Tetracycline.Approved
RotigotineTetracycline may increase the sedative activities of Rotigotine.Approved
RP-5063The risk or severity of adverse effects can be increased when RP-5063 is combined with Tetracycline.Investigational
RucaparibThe serum concentration of Tetracycline can be increased when it is combined with Rucaparib.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Tetracycline.Approved
SafinamideThe risk or severity of adverse effects can be increased when Tetracycline is combined with Safinamide.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Tetracycline.Withdrawn
Salicylic acidThe excretion of Tetracycline can be decreased when combined with Salicylic acid.Approved, Investigational, Vet Approved
SalinomycinThe serum concentration of Tetracycline can be increased when it is combined with Salinomycin.Vet Approved
Salmonella typhi Ty21a live antigenThe therapeutic efficacy of Salmonella typhi Ty21a live antigen can be decreased when used in combination with Tetracycline.Approved
SaquinavirThe metabolism of Tetracycline can be decreased when combined with Saquinavir.Approved, Investigational
SaredutantThe risk or severity of adverse effects can be increased when Saredutant is combined with Tetracycline.Investigational
SarilumabThe therapeutic efficacy of Tetracycline can be decreased when used in combination with Sarilumab.Approved, Investigational
SarpogrelateThe risk or severity of adverse effects can be increased when Tetracycline is combined with Sarpogrelate.Investigational
SaxagliptinThe excretion of Saxagliptin can be decreased when combined with Tetracycline.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tetracycline.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tetracycline.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Tetracycline.Approved, Investigational, Vet Approved
SerotoninThe risk or severity of adverse effects can be increased when Tetracycline is combined with Serotonin.Investigational, Nutraceutical
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Tetracycline.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tetracycline.Approved, Vet Approved
SibutramineThe risk or severity of adverse effects can be increased when Sibutramine is combined with Tetracycline.Approved, Illicit, Investigational, Withdrawn
Silibinin AThe excretion of Silibinin A can be decreased when combined with Tetracycline.Experimental, Investigational
SiltuximabThe serum concentration of Tetracycline can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Tetracycline can be increased when it is combined with Simeprevir.Approved
SisomicinThe risk or severity of adverse effects can be increased when Tetracycline is combined with Sisomicin.Investigational
SitagliptinThe excretion of Sitagliptin can be decreased when combined with Tetracycline.Approved, Investigational
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium feredetateTetracycline can cause a decrease in the absorption of Sodium feredetate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Tetracycline.Approved
SorafenibThe serum concentration of Tetracycline can be increased when it is combined with Sorafenib.Approved, Investigational
St. John's WortThe serum concentration of Tetracycline can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StaurosporineThe serum concentration of Tetracycline can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Tetracycline can be increased when it is combined with Stiripentol.Approved
StreptomycinThe risk or severity of adverse effects can be increased when Streptomycin is combined with Tetracycline.Approved, Vet Approved
Strontium ranelateThe serum concentration of Tetracycline can be decreased when it is combined with Strontium ranelate.Approved, Withdrawn
StyramateThe risk or severity of adverse effects can be increased when Styramate is combined with Tetracycline.Experimental
Succinic acidThe excretion of Succinic acid can be decreased when combined with Tetracycline.Approved, Nutraceutical
SuccinylcholineThe therapeutic efficacy of Succinylcholine can be increased when used in combination with Tetracycline.Approved
SucralfateSucralfate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tetracycline.Approved, Investigational
SulbactamThe therapeutic efficacy of Sulbactam can be decreased when used in combination with Tetracycline.Approved
SulbenicillinThe therapeutic efficacy of Sulbenicillin can be decreased when used in combination with Tetracycline.Experimental
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tetracycline.Approved, Investigational
SultamicillinThe therapeutic efficacy of Sultamicillin can be decreased when used in combination with Tetracycline.Approved, Investigational
SulthiameThe risk or severity of adverse effects can be increased when Sulthiame is combined with Tetracycline.Experimental
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Tetracycline.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Tetracycline is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Tetracycline can be increased when it is combined with Sunitinib.Approved, Investigational
SuvorexantTetracycline may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TacrolimusThe serum concentration of Tetracycline can be increased when it is combined with Tacrolimus.Approved, Investigational
TalampicillinThe therapeutic efficacy of Talampicillin can be decreased when used in combination with Tetracycline.Experimental
TalbutalThe risk or severity of adverse effects can be increased when Talbutal is combined with Tetracycline.Approved, Illicit
TalopramThe risk or severity of adverse effects can be increased when Talopram is combined with Tetracycline.Experimental
TamoxifenThe serum concentration of Tetracycline can be increased when it is combined with Tamoxifen.Approved
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Tetracycline.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Tetracycline.Approved
TariquidarThe serum concentration of Tetracycline can be increased when it is combined with Tariquidar.Investigational
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Tetracycline.Approved, Investigational
Taurocholic AcidThe excretion of Tetracycline can be decreased when combined with Taurocholic Acid.Experimental
TazobactamThe therapeutic efficacy of Tazobactam can be decreased when used in combination with Tetracycline.Approved
TD-8954The risk or severity of adverse effects can be increased when Tetracycline is combined with TD-8954.Investigational
Technetium Tc-99m oxidronateTetracycline can cause a decrease in the absorption of Technetium Tc-99m oxidronate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Tedizolid phosphateThe risk or severity of adverse effects can be increased when Tetracycline is combined with Tedizolid phosphate.Approved
TegaserodThe risk or severity of adverse effects can be increased when Tetracycline is combined with Tegaserod.Approved, Investigational, Withdrawn
TelaprevirThe metabolism of Tetracycline can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Tetracycline can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Tetracycline can be increased when it is combined with Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Tetracycline.Approved, Investigational
TemocillinThe therapeutic efficacy of Temocillin can be decreased when used in combination with Tetracycline.Approved, Investigational
TemsirolimusThe serum concentration of Tetracycline can be increased when it is combined with Temsirolimus.Approved
Tenofovir disoproxilThe excretion of Tenofovir disoproxil can be decreased when combined with Tetracycline.Approved, Investigational
TenoxicamThe excretion of Tetracycline can be decreased when combined with Tenoxicam.Approved
TerfenadineThe serum concentration of Tetracycline can be increased when it is combined with Terfenadine.Approved, Withdrawn
TeriflunomideThe excretion of Tetracycline can be decreased when combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Tetracycline can be increased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Tetracycline can be increased when it is combined with Testosterone.Approved, Investigational
Testosterone cypionateThe serum concentration of Tetracycline can be increased when it is combined with Testosterone cypionate.Approved
Testosterone enanthateThe serum concentration of Tetracycline can be increased when it is combined with Testosterone enanthate.Approved
Testosterone undecanoateThe serum concentration of Tetracycline can be increased when it is combined with Testosterone undecanoate.Approved, Investigational
TetraethylammoniumThe risk or severity of adverse effects can be increased when Tetracycline is combined with Tetraethylammonium.Experimental, Investigational
Tetraferric tricitrate decahydrateTetracycline can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TetrahydrocannabivarinThe risk or severity of adverse effects can be increased when Tetracycline is combined with Tetrahydrocannabivarin.Investigational
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Tetracycline.Investigational
TetrandrineThe serum concentration of Tetracycline can be increased when it is combined with Tetrandrine.Experimental
TetrazepamThe risk or severity of adverse effects can be increased when Tetrazepam is combined with Tetracycline.Experimental
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Tetracycline.Investigational
ThalidomideTetracycline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Tetracycline.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Thiazinam is combined with Tetracycline.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Tetracycline.Withdrawn
ThiocolchicosideThe risk or severity of adverse effects can be increased when Thiocolchicoside is combined with Tetracycline.Approved, Investigational
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Tetracycline.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Thiopropazate is combined with Tetracycline.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Tetracycline.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Tetracycline.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tetracycline.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Tetracycline.Approved, Investigational
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Tetracycline.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Tetracycline.Approved, Investigational
TicagrelorThe serum concentration of Tetracycline can be increased when it is combined with Ticagrelor.Approved
TicarcillinThe therapeutic efficacy of Ticarcillin can be decreased when used in combination with Tetracycline.Approved, Investigational, Vet Approved
TigecyclineThe risk or severity of adverse effects can be increased when Tigecycline is combined with Tetracycline.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Tetracycline.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Tetracycline.Experimental
TioclomarolTetracycline may increase the anticoagulant activities of Tioclomarol.Experimental
TipifarnibThe serum concentration of Tetracycline can be increased when it is combined with Tipifarnib.Investigational
TipranavirThe metabolism of Tetracycline can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Tetracycline.Approved, Investigational
TobramycinThe risk or severity of adverse effects can be increased when Tetracycline is combined with Tobramycin.Approved, Investigational
TocilizumabThe serum concentration of Tetracycline can be decreased when it is combined with Tocilizumab.Approved
TofisopamThe risk or severity of adverse effects can be increased when Tofisopam is combined with Tetracycline.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Tetracycline.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Tetracycline.Approved
TolperisoneThe risk or severity of adverse effects can be increased when Tolperisone is combined with Tetracycline.Approved, Investigational
TolvaptanThe serum concentration of Tetracycline can be increased when it is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Tetracycline.Approved
TopiroxostatThe excretion of Tetracycline can be decreased when combined with Topiroxostat.Approved, Investigational
ToremifeneThe serum concentration of Tetracycline can be increased when it is combined with Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Tetracycline.Approved, Investigational
TramiprosateThe risk or severity of adverse effects can be increased when Tramiprosate is combined with Tetracycline.Investigational
trans-2-hydroxycinnamic acidThe excretion of Tetracycline can be decreased when combined with trans-2-hydroxycinnamic acid.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tetracycline.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Tetracycline is combined with Trazodone.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tetracycline is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Tetracycline.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Tetracycline.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Tetracycline.Approved
TriclofosThe risk or severity of adverse effects can be increased when Triclofos is combined with Tetracycline.Withdrawn
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tetracycline.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Tetracycline.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tetracycline.Approved, Vet Approved
TrifluridineThe excretion of Trifluridine can be decreased when combined with Tetracycline.Approved, Investigational
TrimethadioneThe risk or severity of adverse effects can be increased when Trimethadione is combined with Tetracycline.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Tetracycline is combined with Trimethaphan.Approved, Investigational
TrimethoprimThe serum concentration of Tetracycline can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Tetracycline.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Tetracycline.Approved
TroleandomycinThe metabolism of Tetracycline can be decreased when combined with Troleandomycin.Approved
TropisetronThe risk or severity of adverse effects can be increased when Tetracycline is combined with Tropisetron.Approved, Investigational
TubocurarineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Tubocurarine.Approved
UrapidilThe risk or severity of adverse effects can be increased when Tetracycline is combined with Urapidil.Investigational
VabicaserinThe risk or severity of adverse effects can be increased when Tetracycline is combined with Vabicaserin.Investigational
ValaciclovirThe excretion of Valaciclovir can be decreased when combined with Tetracycline.Approved, Investigational
ValerianThe risk or severity of adverse effects can be increased when Valerian is combined with Tetracycline.Approved, Experimental, Investigational
ValinomycinThe serum concentration of Tetracycline can be increased when it is combined with Valinomycin.Experimental
ValnoctamideThe risk or severity of adverse effects can be increased when Valnoctamide is combined with Tetracycline.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Tetracycline.Approved, Investigational
ValpromideThe risk or severity of adverse effects can be increased when Valpromide is combined with Tetracycline.Experimental
ValspodarThe serum concentration of Tetracycline can be increased when it is combined with Valspodar.Investigational
VancomycinThe risk or severity of adverse effects can be increased when Tetracycline is combined with Vancomycin.Approved
VecuroniumThe therapeutic efficacy of Vecuronium can be increased when used in combination with Tetracycline.Approved
VelpatasvirThe serum concentration of Tetracycline can be increased when it is combined with Velpatasvir.Approved, Investigational
VemurafenibThe serum concentration of Tetracycline can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Tetracycline.Experimental
VerapamilThe serum concentration of Tetracycline can be increased when it is combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Tetracycline.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Tetracycline.Approved
ViloxazineThe risk or severity of adverse effects can be increased when Viloxazine is combined with Tetracycline.Approved, Investigational, Withdrawn
VinbarbitalThe risk or severity of adverse effects can be increased when Vinbarbital is combined with Tetracycline.Experimental
VinblastineThe serum concentration of Tetracycline can be increased when it is combined with Vinblastine.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Vinpocetine is combined with Tetracycline.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Tetracycline.Experimental
VinylbitalThe risk or severity of adverse effects can be increased when Vinylbital is combined with Tetracycline.Experimental
VoacamineThe serum concentration of Tetracycline can be increased when it is combined with Voacamine.Approved, Investigational
VorapaxarThe serum concentration of Tetracycline can be increased when it is combined with Vorapaxar.Approved
VoriconazoleThe metabolism of Tetracycline can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Tetracycline.Approved, Investigational
VoxilaprevirThe serum concentration of Tetracycline can be increased when it is combined with Voxilaprevir.Approved, Investigational
WarfarinTetracycline may increase the anticoagulant activities of Warfarin.Approved
WortmanninThe risk or severity of adverse effects can be increased when Tetracycline is combined with Wortmannin.Experimental
XP19986The risk or severity of adverse effects can be increased when XP19986 is combined with Tetracycline.Investigational
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Tetracycline.Vet Approved
YKP-1358The risk or severity of adverse effects can be increased when Tetracycline is combined with YKP-1358.Investigational
YohimbineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Yohimbine.Approved, Investigational, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Tetracycline.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Tetracycline.Approved
ZidovudineThe excretion of Zidovudine can be decreased when combined with Tetracycline.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Zimelidine.Withdrawn
ZincZinc can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Zinc acetateZinc acetate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Zinc ascorbateZinc ascorbate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Nutraceutical
Zinc carbonateZinc carbonate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Zinc cationZinc cation can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Zinc chlorideZinc chloride can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational
Zinc citrateZinc citrate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Zinc DibutyldithiocarbamateZinc Dibutyldithiocarbamate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Zinc gluconateZinc gluconate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Zinc glycinateZinc glycinate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Zinc oxideZinc oxide can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Zinc picolinateZinc picolinate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Zinc Substituted Heme CZinc Substituted Heme C can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Zinc sulfateZinc sulfate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Zinc sulfate, unspecified formZinc sulfate, unspecified form can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Zinc TrihydroxideZinc Trihydroxide can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Tetracycline.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Tetracycline.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Tetracycline is combined with Zolmitriptan.Approved, Investigational
ZolpidemTetracycline may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZomepiracThe serum concentration of Tetracycline can be increased when it is combined with Zomepirac.Withdrawn
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Tetracycline.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Tetracycline.Approved
ZosuquidarThe serum concentration of Tetracycline can be increased when it is combined with Zosuquidar.Investigational
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Tetracycline.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tetracycline.Approved, Investigational
Food Interactions
  • Avoid milk, calcium containing dairy products, iron, antacids, or aluminium salts 2 hours before or 6 hours after using antacids while on this medication.
  • Take on empty stomach: 1 hour before or 2 hours after meals.
  • Take with a full glass of water.

References

Synthesis Reference

Thomas F. McNamara, Nungavaram S. Ramamurthy, Lorne M. Golub, "Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same." U.S. Patent US4704383, issued May, 1963.

US4704383
General References
  1. Griffin MO, Fricovsky E, Ceballos G, Villarreal F: Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature. Am J Physiol Cell Physiol. 2010 Sep;299(3):C539-48. doi: 10.1152/ajpcell.00047.2010. Epub 2010 Jun 30. [PubMed:20592239]
  2. Link [Link]
External Links
Human Metabolome Database
HMDB0014897
KEGG Drug
D00201
KEGG Compound
C06570
PubChem Compound
54675776
PubChem Substance
46506693
ChemSpider
10257122
ChEBI
27902
ChEMBL
CHEMBL1440
Therapeutic Targets Database
DAP001527
PharmGKB
PA451640
HET
TAC
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Tetracycline
ATC Codes
A02BD08 — Bismuth subcitrate, tetracycline and metronidazoleS02AA08 — TetracyclineA01AB13 — TetracyclineJ01RA08 — Tetracycline and oleandomycinS03AA02 — TetracyclineD06AA04 — TetracyclineJ01AA20 — Combinations of tetracyclinesA02BD02 — Lansoprazole, tetracycline and metronidazoleS01AA09 — TetracyclineJ01AA07 — Tetracycline
AHFS Codes
  • 52:04.04 — Antibacterials
  • 08:12.24 — Tetracyclines
PDB Entries
1hnw / 1i97 / 2hcj / 2hdn / 2trt / 2uxo / 2vke / 3q5p / 4b3a / 4v9a
show 2 more
MSDS
Download (73.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0WithdrawnTreatmentChalazia / Chalazion1
1CompletedTreatmentAcute and Chronic Inflammation / Autoimmune Diseases / Disorder of Pleura and Pleural Cavity / Disorder of Synovium / Felty's Syndrome / Rheumatoid Arthritis / Rheumatoid Nodules / Sjögren's Syndrome1
1CompletedTreatmentAutoimmune Diseases / Disseminated or Multiple Sclerosis Nos / Disseminated Sclerosis / Multiple Sclerosis, Acute Relapsing / Multiple Sclerosis, Chronic Progressive / Multiple Sclerosis, Primary Progressive1
2CompletedTreatmentAlzheimer's Disease (AD) / Mild Cognitive Impairment (MCI)1
2CompletedTreatmentMalignant Lymphomas2
2CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2Unknown StatusTreatmentLung Cancers / Skin Rash1
2, 3TerminatedTreatmentMinor burns1
3CompletedTreatmentHelicobacter Infections1
3RecruitingTreatmentDuodenal Ulcer1
3Unknown StatusTreatmentBacterial Vaginosis (BV) / Candidiasis infection1
3WithdrawnTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)1
4CompletedPreventionTrichiasis1
4CompletedTreatmentCoxiella Infection / Fatigue Syndrome, Chronic / Q Fever1
4CompletedTreatmentCure Rate of Helicobacter Pylori Infection1
4CompletedTreatmentFunctional Dyspepsia / Scarred Peptic Ulcer1
4CompletedTreatmentHelicobacter Infection1
4CompletedTreatmentHelicobacter Infections1
4CompletedTreatmentHelicobacter Pylori Treatment Failure1
4CompletedTreatmentBone destruction1
4Not Yet RecruitingTreatmentAntimicrobial Susceptibility Testing / Bacterial Infection Due to Helicobacter Pylori (H. Pylori)1
4Not Yet RecruitingTreatmentAntimicrobial Susceptibility Testing / Triple Therapy1
4Not Yet RecruitingTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)1
4Not Yet RecruitingTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori) / Gastric Ulcer (GU) / Gastritis / Gastritis Chronic / Malignant Neoplasm of Stomach1
4RecruitingPreventionTrachoma1
4RecruitingTreatmentAntimicrobial Susceptibility Testing / Bacterial Infection Due to Helicobacter Pylori (H. Pylori)1
4RecruitingTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)4
4Unknown StatusTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)1
4Unknown StatusTreatmentEpidermolysis Bullosa1
Not AvailableCompletedBasic ScienceCognitive Dysfunctions / Paresis / Paresthesia / Radicular Pain / Tiredness1
Not AvailableCompletedBasic ScienceOpioid Dependence / Pain1
Not AvailableCompletedSupportive CareUnspecified Adult Solid Tumor, Protocol Specific1
Not AvailableCompletedTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)1
Not AvailableRecruitingTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)3
Not AvailableRecruitingTreatmentHelicobacter Infection1
Not AvailableUnknown StatusTreatmentAngelman's syndrome1
Not AvailableUnknown StatusTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)2
Not AvailableWithdrawnNot AvailableCancer, Breast1

Pharmacoeconomics

Manufacturers
  • Heritage pharmaceuticals inc
  • Bristol laboratories inc div bristol myers co
  • Warner chilcott div warner lambert co
  • Pharmacia and upjohn co
  • Solvay pharmaceuticals
  • Wyeth ayerst laboratories
  • Apothecon inc div bristol myers squibb
  • Angus chemical co
  • Pfipharmecs div pfizer inc
  • On site therapeutics inc
  • Shire development inc
  • Lederle laboratories div american cyanamid co
  • Pfizer laboratories div pfizer inc
  • Storz ophthalmics inc sub american cyanamid co
  • Par pharmaceutical
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Par pharmaceutical inc
Packagers
  • Advanced Pharmaceutical Services Inc.
  • Aidarex Pharmacuticals LLC
  • Apotheca Inc.
  • A-S Medication Solutions LLC
  • Axcan Pharma Inc.
  • Barr Pharmaceuticals
  • Belgomex Sprl
  • Blenheim Pharmacal
  • Bryant Ranch Prepack
  • C.O. Truxton Inc.
  • Central Texas Community Health Centers
  • Comprehensive Consultant Services Inc.
  • Coupler Enterprises Inc.
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Draxis Specialty Pharmaceuticals Inc.
  • E.R. Squibb and Sons LLC
  • Gallipot
  • Global Pharmaceuticals
  • Golden State Medical Supply Inc.
  • Goldline Laboratories Inc.
  • Group Health Cooperative
  • H and H Laboratories
  • H.J. Harkins Co. Inc.
  • Heartland Repack Services LLC
  • Ivax Pharmaceuticals
  • Kaiser Foundation Hospital
  • Laboratorios Atral Sarl
  • Liberty Pharmaceuticals
  • Major Pharmaceuticals
  • Medisca Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Nucare Pharmaceuticals Inc.
  • Palmetto Pharmaceuticals Inc.
  • Par Pharmaceuticals
  • Patient First Corp.
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Prometheus Laboratories Inc.
  • Proter SPA
  • Qualitest
  • Rebel Distributors Corp.
  • Remedy Repack
  • Sandhills Packaging Inc.
  • Sino American Shanghai Squibb Pharmaceutical Ltd.
  • Southwood Pharmaceuticals
  • Talbert Medical Management Corp.
  • Tya Pharmaceuticals
  • Veratex Corp.
  • Warner Chilcott Co. Inc.
  • Watson Pharmaceuticals
Dosage forms
FormRouteStrength
OintmentOphthalmic1 %
Fiber, extended releaseDental12.7 mg
OintmentTopical30 mg/g
OintmentTopical30 mg/mL
KitOral
TabletOral250 mg
LiquidOral125 mg
CapsuleOral
Tablet, film coatedOral250 mg/1
Tablet, film coatedOral500 mg/1
OintmentTopical.03 mg/mL
CapsuleOral250 mg
OintmentOphthalmic10 mg
CapsuleOral250 mg/1
CapsuleOral500 mg/1
Prices
Unit descriptionCostUnit
Tetracycline hcl powder2.14USD g
Tetracycline powder1.37USD g
Tetracycline HCl 500 mg capsule0.2USD capsule
Tetracycline HCl 250 mg capsule0.15USD capsule
Apo-Tetra 250 mg Capsule0.07USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6350468No1998-12-142018-12-14Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)172.5 dec °CPhysProp
water solubility231 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP-1.30HANSCH,C ET AL. (1995)
logS-3.12ADME Research, USCD
pKa3.3 (at 25 °C)SERJEANT,EP & DEMPSEY,B (1979)
Predicted Properties
PropertyValueSource
Water Solubility1.33 mg/mLALOGPS
logP-0.56ALOGPS
logP-3.5ChemAxon
logS-2.5ALOGPS
pKa (Strongest Acidic)-2.2ChemAxon
pKa (Strongest Basic)8.24ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area181.62 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity114.19 m3·mol-1ChemAxon
Polarizability43.03 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8006
Blood Brain Barrier-0.9841
Caco-2 permeable+0.7439
P-glycoprotein substrateSubstrate0.791
P-glycoprotein inhibitor INon-inhibitor0.8025
P-glycoprotein inhibitor IINon-inhibitor0.7562
Renal organic cation transporterNon-inhibitor0.9437
CYP450 2C9 substrateNon-substrate0.7897
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateSubstrate0.6758
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9089
CYP450 3A4 inhibitorNon-inhibitor0.8686
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.781
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9314
BiodegradationNot ready biodegradable0.9906
Rat acute toxicity2.7095 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9968
hERG inhibition (predictor II)Non-inhibitor0.7201
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-01sc-1900000000-7b792268aeb0a63c32c5
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-01p9-1900000000-da0b69e206bb0369723c
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-000i-3900000000-299e4496b1f8e2f213cc
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-01ta-0000900000-e5ca6594fe72eb2bcd1f
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0ik9-0402900000-9ef4a0d08180ce9b2a1c

Taxonomy

Description
This compound belongs to the class of organic compounds known as tetracyclines. These are polyketides having an octahydrotetracene-2-carboxamide skeleton, substituted with many hydroxy and other groups.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Tetracyclines
Sub Class
Not Available
Direct Parent
Tetracyclines
Alternative Parents
Naphthacenes / Anthracenecarboxylic acids and derivatives / Tetralins / Aryl ketones / 1-hydroxy-2-unsubstituted benzenoids / 1-hydroxy-4-unsubstituted benzenoids / Aralkylamines / Cyclohexenones / Tertiary alcohols / Vinylogous acids
show 8 more
Substituents
Tetracycline / Naphthacene / Tetracene / Anthracene carboxylic acid or derivatives / Tetralin / Aryl ketone / 1-hydroxy-4-unsubstituted benzenoid / 1-hydroxy-2-unsubstituted benzenoid / Cyclohexenone / Aralkylamine
show 23 more
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
tetracyclines (CHEBI:27902) / tetracyclines, Linear tetracyclines (C06570)

Targets

Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Trna binding
Specific Function
One of the primary rRNA binding proteins, it binds directly to 16S rRNA where it nucleates assembly of the head domain of the 30S subunit. Is located at the subunit interface close to the decoding ...
Gene Name
rpsG
Uniprot ID
P02359
Uniprot Name
30S ribosomal protein S7
Molecular Weight
20018.91 Da
References
  1. Buck MA, Cooperman BS: Single protein omission reconstitution studies of tetracycline binding to the 30S subunit of Escherichia coli ribosomes. Biochemistry. 1990 Jun 5;29(22):5374-9. [PubMed:2200507]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Structural constituent of ribosome
Specific Function
Binds 16S rRNA, required for the assembly of 30S particles and may also be responsible for determining the conformation of the 16S rRNA at the A site.
Gene Name
rpsN
Uniprot ID
P0AG59
Uniprot Name
30S ribosomal protein S14
Molecular Weight
11580.36 Da
References
  1. Buck MA, Cooperman BS: Single protein omission reconstitution studies of tetracycline binding to the 30S subunit of Escherichia coli ribosomes. Biochemistry. 1990 Jun 5;29(22):5374-9. [PubMed:2200507]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Structural constituent of ribosome
Specific Function
Binds the lower part of the 30S subunit head. Binds mRNA in the 70S ribosome, positioning it for translation (By similarity).Plays a role in mRNA unwinding by the ribosome, possibly by forming part...
Gene Name
rpsC
Uniprot ID
P0A7V3
Uniprot Name
30S ribosomal protein S3
Molecular Weight
25983.07 Da
References
  1. Buck MA, Cooperman BS: Single protein omission reconstitution studies of tetracycline binding to the 30S subunit of Escherichia coli ribosomes. Biochemistry. 1990 Jun 5;29(22):5374-9. [PubMed:2200507]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Structural constituent of ribosome
Specific Function
One of the primary rRNA binding proteins, it binds directly to 16S rRNA central domain where it helps coordinate assembly of the platform of the 30S subunit.Protein S8 is a translational repressor ...
Gene Name
rpsH
Uniprot ID
P0A7W7
Uniprot Name
30S ribosomal protein S8
Molecular Weight
14126.435 Da
References
  1. Buck MA, Cooperman BS: Single protein omission reconstitution studies of tetracycline binding to the 30S subunit of Escherichia coli ribosomes. Biochemistry. 1990 Jun 5;29(22):5374-9. [PubMed:2200507]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Trna binding
Specific Function
In the E.coli 70S ribosome in the initiation state (PubMed:12809609) it has been modeled to contact the 23S rRNA of the 50S subunit forming part of bridge B1a; this bridge is broken in the model wi...
Gene Name
rpsS
Uniprot ID
P0A7U3
Uniprot Name
30S ribosomal protein S19
Molecular Weight
10430.235 Da
References
  1. Buck MA, Cooperman BS: Single protein omission reconstitution studies of tetracycline binding to the 30S subunit of Escherichia coli ribosomes. Biochemistry. 1990 Jun 5;29(22):5374-9. [PubMed:2200507]
6. 16S rRNA
Kind
Nucleotide
Organism
Enteric bacteria and other eubacteria
Pharmacological action
Yes
Actions
Inhibitor
References
  1. Nawaz M, Sung K, Khan SA, Khan AA, Steele R: Biochemical and molecular characterization of tetracycline-resistant Aeromonas veronii isolates from catfish. Appl Environ Microbiol. 2006 Oct;72(10):6461-6. [PubMed:17021193]
  2. Domingue GJ Sr: Cryptic bacterial infection in chronic prostatitis: diagnostic and therapeutic implications. Curr Opin Urol. 1998 Jan;8(1):45-9. [PubMed:17035842]
  3. Pringle M, Fellstrom C, Johansson KE: Decreased susceptibility to doxycycline associated with a 16S rRNA gene mutation in Brachyspira hyodysenteriae. Vet Microbiol. 2007 Jul 20;123(1-3):245-8. Epub 2007 Feb 25. [PubMed:17428623]
  4. Rasmussen B, Noller HF, Daubresse G, Oliva B, Misulovin Z, Rothstein DM, Ellestad GA, Gluzman Y, Tally FP, Chopra I: Molecular basis of tetracycline action: identification of analogs whose primary target is not the bacterial ribosome. Antimicrob Agents Chemother. 1991 Nov;35(11):2306-11. [PubMed:1725100]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Tubulin binding
Specific Function
Its primary physiological function is unclear. Has cytoprotective activity against internal or environmental stresses. May play a role in neuronal development and synaptic plasticity. May be requir...
Gene Name
PRNP
Uniprot ID
P04156
Uniprot Name
Major prion protein
Molecular Weight
27661.21 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. De Luigi A, Colombo L, Diomede L, Capobianco R, Mangieri M, Miccolo C, Limido L, Forloni G, Tagliavini F, Salmona M: The efficacy of tetracyclines in peripheral and intracerebral prion infection. PLoS One. 2008 Mar 26;3(3):e1888. doi: 10.1371/journal.pone.0001888. [PubMed:18365024]
Kind
Protein
Organism
Escherichia coli
Pharmacological action
Unknown
General Function
Transporter activity
Specific Function
Not Available
Gene Name
mdfA
Uniprot ID
C9EH48
Uniprot Name
Multidrug translocase MdfA
Molecular Weight
10133.045 Da
References
  1. Nelson ML, Park BH, Andrews JS, Georgian VA, Thomas RC, Levy SB: Inhibition of the tetracycline efflux antiport protein by 13-thio-substituted 5-hydroxy-6-deoxytetracyclines. J Med Chem. 1993 Feb 5;36(3):370-7. [PubMed:8426364]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Protein-arginine deiminase activity
Specific Function
Catalyzes the citrullination/deimination of arginine residues of proteins such as histones, thereby playing a key role in histone code and regulation of stem cell maintenance. Citrullinates histone...
Gene Name
PADI4
Uniprot ID
Q9UM07
Uniprot Name
Protein-arginine deiminase type-4
Molecular Weight
74078.65 Da
References
  1. Knuckley B, Luo Y, Thompson PR: Profiling Protein Arginine Deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors. Bioorg Med Chem. 2008 Jan 15;16(2):739-45. Epub 2007 Oct 13. [PubMed:17964793]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
No
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Bratlid D, Bergan T: Displacement of albumin-bound antimicrobial agents by bilirubin. Pharmacology. 1976;14(5):464-72. [PubMed:1031216]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Babu E, Takeda M, Narikawa S, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Sakthisekaran D, Endou H: Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76. [PubMed:11855680]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Curator comments
Substrate activity was observed in vitro using hOAT3 expressed on S2 cells. Reported Km value was 566.2 ± 28.4 μM.
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da
References
  1. Babu E, Takeda M, Narikawa S, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Sakthisekaran D, Endou H: Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76. [PubMed:11855680]
  2. VanWert AL, Gionfriddo MR, Sweet DH: Organic anion transporters: discovery, pharmacology, regulation and roles in pathophysiology. Biopharm Drug Dispos. 2010 Jan;31(1):1-71. doi: 10.1002/bdd.693. [PubMed:19953504]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name
SLC22A11
Uniprot ID
Q9NSA0
Uniprot Name
Solute carrier family 22 member 11
Molecular Weight
59970.945 Da
References
  1. Babu E, Takeda M, Narikawa S, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Sakthisekaran D, Endou H: Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76. [PubMed:11855680]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulf...
Gene Name
SLC22A7
Uniprot ID
Q9Y694
Uniprot Name
Solute carrier family 22 member 7
Molecular Weight
60025.025 Da
References
  1. Babu E, Takeda M, Narikawa S, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Sakthisekaran D, Endou H: Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76. [PubMed:11855680]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name
SLCO2B1
Uniprot ID
O94956
Uniprot Name
Solute carrier organic anion transporter family member 2B1
Molecular Weight
76709.98 Da
References
  1. Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P: Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem. 2012 May 24;55(10):4740-63. doi: 10.1021/jm300212s. Epub 2012 May 15. [PubMed:22541068]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:44